<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="pharmOncoX">
<title>Getting started â€¢ pharmOncoX</title>
<!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
<link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png">
<link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png">
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Getting started">
<meta property="og:description" content="pharmOncoX">
<meta property="og:image" content="https://sigven.github.io/pharmOncoX/logo.png">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.1.4</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="active nav-item">
  <a class="nav-link" href="../articles/pharmOncoX.html">Getting started</a>
</li>
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/sigven/pharmOncoX/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">



<script src="pharmOncoX_files/htmlwidgets-1.6.1/htmlwidgets.js"></script><link href="pharmOncoX_files/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet">
<script src="pharmOncoX_files/datatables-binding-0.26/datatables.js"></script><link href="pharmOncoX_files/dt-core-1.12.1/css/jquery.dataTables.min.css" rel="stylesheet">
<link href="pharmOncoX_files/dt-core-1.12.1/css/jquery.dataTables.extra.css" rel="stylesheet">
<script src="pharmOncoX_files/dt-core-1.12.1/js/jquery.dataTables.min.js"></script><script src="pharmOncoX_files/jszip-1.12.1/jszip.min.js"></script><link href="pharmOncoX_files/dt-ext-buttons-1.12.1/css/buttons.dataTables.min.css" rel="stylesheet">
<script src="pharmOncoX_files/dt-ext-buttons-1.12.1/js/dataTables.buttons.min.js"></script><script src="pharmOncoX_files/dt-ext-buttons-1.12.1/js/buttons.html5.min.js"></script><script src="pharmOncoX_files/dt-ext-buttons-1.12.1/js/buttons.colVis.min.js"></script><script src="pharmOncoX_files/dt-ext-buttons-1.12.1/js/buttons.print.min.js"></script><link href="pharmOncoX_files/dt-ext-responsive-1.12.1/css/responsive.dataTables.min.css" rel="stylesheet">
<script src="pharmOncoX_files/dt-ext-responsive-1.12.1/js/dataTables.responsive.min.js"></script><link href="pharmOncoX_files/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet">
<script src="pharmOncoX_files/crosstalk-1.2.0/js/crosstalk.min.js"></script><div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>Getting started</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/sigven/pharmOncoX/blob/HEAD/vignettes/pharmOncoX.Rmd" class="external-link"><code>vignettes/pharmOncoX.Rmd</code></a></small>
      <div class="d-none name"><code>pharmOncoX.Rmd</code></div>
    </div>

    
    
<p><br><br></p>
<div class="section level2">
<h2 id="installation">Installation<a class="anchor" aria-label="anchor" href="#installation"></a>
</h2>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a><span class="cf">if</span> (<span class="sc">!</span>(<span class="st">"remotes"</span> <span class="sc">%in%</span> <span class="fu">installed.packages</span>()) {</span>
<span id="cb1-3"><a href="#cb1-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">install.packages</span>(<span class="st">"remotes"</span>)</span>
<span id="cb1-4"><a href="#cb1-4" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb1-5"><a href="#cb1-5" aria-hidden="true" tabindex="-1"></a>remotes<span class="sc">::</span><span class="fu">install_github</span>(<span class="st">'sigven/pharmOncoX'</span>)</span></code></pre></div>
<p><br><br></p>
</div>
<div class="section level2">
<h2 id="retrieval-of-drugs---examples">Retrieval of drugs - examples<a class="anchor" aria-label="anchor" href="#retrieval-of-drugs---examples"></a>
</h2>
<div class="section level3">
<h3 id="get-braf-targeted-drugs-list-records-per-indication">Get BRAF-targeted drugs, list records per indication<a class="anchor" aria-label="anchor" href="#get-braf-targeted-drugs-list-records-per-indication"></a>
</h3>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/sigven/pharmOncoX" class="external-link">pharmOncoX</a></span><span class="op">)</span></span>
<span></span>
<span><span class="co">## load the data</span></span>
<span><span class="va">cache_dir</span> <span class="op">&lt;-</span> <span class="fu"><a href="https://rdrr.io/r/base/tempfile.html" class="external-link">tempdir</a></span><span class="op">(</span><span class="op">)</span></span>
<span></span>
<span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
<span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>,</span>
<span>  drug_is_targeted <span class="op">=</span> <span class="cn">T</span>,</span>
<span>    drug_target <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">'BRAF'</span><span class="op">)</span><span class="op">)</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:16] Downloading remote dataset from Google Drive to cache_dir</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:18] Reading from cache_dir = ' (/tmp/RtmpvilFeM'), argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:18] Object 'drug_map_name' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:18] md5 checksum is valid: 750a21ac4659485f8cefbe0448a86476</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:18] Retrieved 7653 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:18] Downloading remote dataset from Google Drive to cache_dir</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:21] Reading from cache_dir = ' (/tmp/RtmpvilFeM'), argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:21] Object 'drug_map_alias' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:21] md5 checksum is valid: 6917e16645733b8f36e3b4b647d207a1</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:21] Retrieved 187616 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:21] Downloading remote dataset from Google Drive to cache_dir</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:24] Reading from cache_dir = ' (/tmp/RtmpvilFeM'), argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:24] Object 'drug_map_basic' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:24] md5 checksum is valid: cf81a17879b07b9b3f00c5daeae0b6ba</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:24] Retrieved 7654 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:24] Downloading remote dataset from Google Drive to cache_dir</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:26] Reading from cache_dir = ' (/tmp/RtmpvilFeM'), argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:26] Object 'drug_map_target' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:26] md5 checksum is valid: 63e92b8cef50bed0055874cf4ec9e269</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:26] Retrieved 11822 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:26] Downloading remote dataset from Google Drive to cache_dir</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:28] Reading from cache_dir = ' (/tmp/RtmpvilFeM'), argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:28] Object 'drug_map_indication' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:28] md5 checksum is valid: d1226c4dfae20573a8a1992af9bc4998</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:28] Retrieved 28407 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:29] Record set satisfying user-defined criteria: n = 284</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:29] Collapsing record set - providing output on a 'per_drug_target_indication' resolution</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:29] Final record set: n = 237 records</span></span>
<span></span>
<span><span class="co">## Number of drug records</span></span>
<span><span class="fu"><a href="https://rdrr.io/r/base/nrow.html" class="external-link">nrow</a></span><span class="op">(</span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span><span class="op">)</span></span>
<span><span class="co">#&gt; [1] 237</span></span>
<span></span>
<span><span class="co">## Column names of drug records</span></span>
<span><span class="fu"><a href="https://rdrr.io/r/base/colnames.html" class="external-link">colnames</a></span><span class="op">(</span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span><span class="op">)</span></span>
<span><span class="co">#&gt;  [1] "drug_id"                     "drug_name"                  </span></span>
<span><span class="co">#&gt;  [3] "drug_type"                   "molecule_chembl_id"         </span></span>
<span><span class="co">#&gt;  [5] "drug_action_type"            "drug_alias"                 </span></span>
<span><span class="co">#&gt;  [7] "nci_concept_definition"      "opentargets"                </span></span>
<span><span class="co">#&gt;  [9] "inhibition_moa"              "is_salt"                    </span></span>
<span><span class="co">#&gt; [11] "is_adc"                      "drug_blackbox_warning"      </span></span>
<span><span class="co">#&gt; [13] "nci_t"                       "immune_checkpoint_inhibitor"</span></span>
<span><span class="co">#&gt; [15] "topoisomerase_inhibitor"     "iap_inhibitor"              </span></span>
<span><span class="co">#&gt; [17] "tubulin_inhibitor"           "kinase_inhibitor"           </span></span>
<span><span class="co">#&gt; [19] "hdac_inhibitor"              "parp_inhibitor"             </span></span>
<span><span class="co">#&gt; [21] "bet_inhibitor"               "monoclonal_antibody"        </span></span>
<span><span class="co">#&gt; [23] "antimetabolite"              "angiogenesis_inhibitor"     </span></span>
<span><span class="co">#&gt; [25] "alkylating_agent"            "anthracycline"              </span></span>
<span><span class="co">#&gt; [27] "platinum_compound"           "proteasome_inhibitor"       </span></span>
<span><span class="co">#&gt; [29] "hormone_therapy"             "hedgehog_antagonist"        </span></span>
<span><span class="co">#&gt; [31] "fda_epc_category"            "target_symbol"              </span></span>
<span><span class="co">#&gt; [33] "target_entrezgene"           "target_genename"            </span></span>
<span><span class="co">#&gt; [35] "target_ensembl_gene_id"      "target_type"                </span></span>
<span><span class="co">#&gt; [37] "drug_max_phase_indication"   "drug_approved_indication"   </span></span>
<span><span class="co">#&gt; [39] "drug_year_first_approval"    "drug_max_ct_phase"          </span></span>
<span><span class="co">#&gt; [41] "disease_efo_id"              "disease_efo_label"          </span></span>
<span><span class="co">#&gt; [43] "primary_site"                "drug_clinical_id"           </span></span>
<span><span class="co">#&gt; [45] "drug_clinical_source"</span></span></code></pre></div>
<p><br><br></p>
</div>
<div class="section level3">
<h3 id="get-braf-targeted-drugs-open-targets-platform-only-list-per-drug-only">Get BRAF-targeted drugs, Open Targets Platform only, list per drug
only<a class="anchor" aria-label="anchor" href="#get-braf-targeted-drugs-open-targets-platform-only-list-per-drug-only"></a>
</h3>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span></span>
<span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
<span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
<span>  drug_is_targeted <span class="op">=</span> <span class="cn">T</span>,</span>
<span>    drug_target <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">'BRAF'</span><span class="op">)</span>, </span>
<span>  source_opentargets_only <span class="op">=</span> <span class="cn">T</span>, </span>
<span>  output_resolution <span class="op">=</span> <span class="st">"drug"</span> <span class="op">)</span></span>
<span></span>
<span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> </span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>    <span class="op">-</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"drug_alias"</span>,</span>
<span>       <span class="st">"disease_main_group"</span>,</span>
<span>       <span class="st">"drug_clinical_id"</span><span class="op">)</span><span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/mutate.html" class="external-link">mutate</a></span><span class="op">(</span></span>
<span>    disease_indication <span class="op">=</span> <span class="fu">stringr</span><span class="fu">::</span><span class="fu"><a href="https://stringr.tidyverse.org/reference/str_replace.html" class="external-link">str_replace_all</a></span><span class="op">(</span></span>
<span>      <span class="va">disease_indication</span>, <span class="st">"\\|"</span>,<span class="st">", "</span><span class="op">)</span></span>
<span>    <span class="op">)</span></span>
<span></span>
<span><span class="va">dt_drugtable1</span> <span class="op">&lt;-</span> <span class="fu">DT</span><span class="fu">::</span><span class="fu"><a href="https://rdrr.io/pkg/DT/man/datatable.html" class="external-link">datatable</a></span><span class="op">(</span></span>
<span>  <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>  escape <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  extensions <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"Buttons"</span>, <span class="st">"Responsive"</span><span class="op">)</span>, </span>
<span>  width <span class="op">=</span> <span class="st">"100%"</span>,</span>
<span>  options <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span></span>
<span>    buttons <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"csv"</span>, <span class="st">"excel"</span><span class="op">)</span>, </span>
<span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
<span><span class="op">)</span></span></code></pre></div>
<p><br></p>
<div id="htmlwidget-37d7aeb62eed7e2b50f2" style="width:100%;height:auto;" class="datatables html-widget "></div>
<script type="application/json" data-for="htmlwidget-37d7aeb62eed7e2b50f2">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15"],[3209,2743,6354,7456,6747,5239,1849,1283,6013,227,4540,7208,6231,5670,1762],["Encorafenib","Dabrafenib","Regorafenib","Vemurafenib","Sorafenib","Naporafenib","Belvarafenib","ARQ-736","PLX-8394","Agerafenib","Lifirafenib","Tovorafenib","RAF Kinase Inhibitor XL281","Pan-RAF Inhibitor LY3009120","B-Raf/VEGFR-2 Inhibitor RAF265"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL3301612","CHEMBL2028663","CHEMBL1946170","CHEMBL1229517","CHEMBL1336","CHEMBL4583691","CHEMBL3977543","CHEMBL3545296","CHEMBL3545005","CHEMBL2029988","CHEMBL4209157","CHEMBL3348923","CHEMBL3545027","CHEMBL3545195","CHEMBL558752"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","NA","NA","An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C98283","C82386","C78204","C64768","C61948","C125003","C121646","NA","NA","C107245","C124995","C106254","C69135","C116861","C61311"],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,true,false,true,false,false,false,false,false,false,false,false,false,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[null,null,null,"Kinase Inhibitor [EPC]","Kinase Inhibitor [EPC]",null,null,null,null,null,null,null,null,null,null],[2018,2013,2012,2011,2005,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,2,2,1,1,1,1,1,1,1,1],["cancer, colorectal adenocarcinoma, colorectal carcinoma, cutaneous melanoma, hairy cell leukemia, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, pancreatic carcinoma, thyroid carcinoma","ameloblastoma, brain neoplasm, cancer, cutaneous melanoma, erdheim-chester disease, follicular thyroid carcinoma, lung cancer, malignant glioma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, papillary thyroid carcinoma, thyroid cancer, thyroid carcinoma","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, bile duct carcinoma, biliary tract cancer, cancer, cholangiocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, fallopian tube cancer, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, hepatocellular carcinoma, liposarcoma, malignant colon neoplasm, melanoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, thyroid cancer","acute myeloid leukemia, cancer, central nervous system cancer, colorectal adenocarcinoma, colorectal carcinoma, craniopharyngioma, cutaneous melanoma, hairy cell leukemia, histiocytosis, langerhans cell histiocytosis, lymphoma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, skin cancer, skin carcinoma, thyroid cancer, thyroid carcinoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adrenal cortex carcinoma, anaplastic astrocytoma, anaplastic large cell lymphoma, anaplastic oligodendroglioma, brain neoplasm, breast cancer, cancer, carcinoma of liver and intrahepatic biliary tract, cervical carcinoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, esophageal cancer, fallopian tube cancer, follicular thyroid carcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, kaposi's sarcoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung cancer, lymphoma, male breast carcinoma, malignant colon neoplasm, mantle cell lymphoma, medullary thyroid gland carcinoma, melanoma, mesothelioma, metastatic prostate cancer, multiple myeloma, myeloid sarcoma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oropharyngeal carcinoma, osteosarcoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic neoplasm, papillary renal cell carcinoma, papillary thyroid carcinoma, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectal carcinoma, rectum cancer, rhabdomyosarcoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, testicular carcinoma, thyroid cancer, thyroid carcinoma, thyroid neoplasm, tongue neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, uterine carcinosarcoma, verrucous carcinoma","melanoma, non-small cell lung carcinoma","cancer, melanoma","cancer","cancer, cholangiocarcinoma, colorectal carcinoma, hairy cell leukemia, histiocytosis, melanoma, non-small cell lung carcinoma, thyroid cancer","cancer","cancer","cancer, melanoma, metastatic melanoma","colorectal carcinoma, melanoma, non-small cell lung carcinoma, papillary thyroid carcinoma","colorectal neoplasm, melanoma, non-small cell lung carcinoma","cancer, metastatic melanoma"],["2|4","1|2|3|4","1|2|3|4","0|1|2|4","1|2|3|4","1|2","1|2","1","1","1","1","1","1","1","1"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>immune_checkpoint_inhibitor<\/th>\n      <th>topoisomerase_inhibitor<\/th>\n      <th>iap_inhibitor<\/th>\n      <th>tubulin_inhibitor<\/th>\n      <th>kinase_inhibitor<\/th>\n      <th>hdac_inhibitor<\/th>\n      <th>parp_inhibitor<\/th>\n      <th>bet_inhibitor<\/th>\n      <th>monoclonal_antibody<\/th>\n      <th>antimetabolite<\/th>\n      <th>angiogenesis_inhibitor<\/th>\n      <th>alkylating_agent<\/th>\n      <th>anthracycline<\/th>\n      <th>platinum_compound<\/th>\n      <th>proteasome_inhibitor<\/th>\n      <th>hormone_therapy<\/th>\n      <th>hedgehog_antagonist<\/th>\n      <th>fda_epc_category<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indicaton_max_phase<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,31,32]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
</div>
<div class="section level3">
<h3 id="get-immune-checkpoint-inhibitors-list-per-drug-target-entry">Get immune checkpoint inhibitors, list per drug-target entry<a class="anchor" aria-label="anchor" href="#get-immune-checkpoint-inhibitors-list-per-drug-target-entry"></a>
</h3>
<div class="sourceCode" id="cb4"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span></span>
<span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
<span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
<span>  is_immune_checkpoint_inhibitor <span class="op">=</span> <span class="cn">T</span>,</span>
<span>   output_resolution <span class="op">=</span> <span class="st">"drug2target"</span><span class="op">)</span></span>
<span></span>
<span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> </span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>    <span class="op">-</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"drug_alias"</span>,</span>
<span>       <span class="st">"disease_main_group"</span>,</span>
<span>       <span class="st">"drug_clinical_id"</span><span class="op">)</span><span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/mutate.html" class="external-link">mutate</a></span><span class="op">(</span></span>
<span>    disease_indication <span class="op">=</span> <span class="fu">stringr</span><span class="fu">::</span><span class="fu"><a href="https://stringr.tidyverse.org/reference/str_replace.html" class="external-link">str_replace_all</a></span><span class="op">(</span></span>
<span>      <span class="va">disease_indication</span>, <span class="st">"\\|"</span>,<span class="st">", "</span><span class="op">)</span></span>
<span>    <span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drug_id</span>,</span>
<span>    <span class="va">drug_name</span>,</span>
<span>    <span class="va">drug_type</span>,</span>
<span>    <span class="va">target_symbol</span>,</span>
<span>    <span class="va">target_genename</span>,</span>
<span>    <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://tidyselect.r-lib.org/reference/everything.html" class="external-link">everything</a></span><span class="op">(</span><span class="op">)</span></span>
<span>  <span class="op">)</span></span>
<span></span>
<span><span class="va">dt_drugtable2</span> <span class="op">&lt;-</span> <span class="fu">DT</span><span class="fu">::</span><span class="fu"><a href="https://rdrr.io/pkg/DT/man/datatable.html" class="external-link">datatable</a></span><span class="op">(</span></span>
<span>  <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>  escape <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  extensions <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"Buttons"</span>, <span class="st">"Responsive"</span><span class="op">)</span>, </span>
<span>  width <span class="op">=</span> <span class="st">"100%"</span>,</span>
<span>  options <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span></span>
<span>    buttons <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"csv"</span>, <span class="st">"excel"</span><span class="op">)</span>, </span>
<span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
<span><span class="op">)</span></span></code></pre></div>
<p><br></p>
<div id="htmlwidget-857950bddfed5354d290" style="width:100%;height:auto;" class="datatables html-widget "></div>
<script type="application/json" data-for="htmlwidget-857950bddfed5354d290">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276"],[3003,2386,1719,3048,1315,5355,5794,4299,2409,5805,6568,6677,1777,5418,6195,6626,6826,7132,7200,2161,2989,3307,3307,6166,6392,7136,7253,7481,7629,6771,1945,1945,1945,1945,1254,5627,2131,2131,3251,5949,6972,6972,7601,4083,3373,2083,4627,4764,4923,2485,1053,1155,1168,3205,4733,7546,7546,4373,4475,5521,6370,6370,7625,116,116,167,408,1781,1846,2778,3464,4542,4588,4632,5511,5720,5720,6063,6126,6522,6911,7120,7162,7532,7614,2766,2796,3513,3761,4641,4739,4940,5366,6887,7339,1899,5757,6240,6443,6848,3267,3099,5745,6081,5740,2673,5747,5746,5749,65,4223,5357,5748,5750,968,1102,5738,2328,819,1080,1139,1164,1473,2320,1054,1059,6689,736,1060,1064,1086,5755,5755,5755,7482,996,1062,1063,1084,1154,735,739,818,999,1002,1055,1056,1057,1072,1072,1082,1083,1097,1127,1128,1159,1161,1166,3465,3465,734,738,810,811,813,814,817,973,997,998,1009,1010,1058,1061,1081,1156,1157,1160,1167,1169,174,582,815,1085,1153,6690,170,173,765,812,816,1050,1077,1078,1101,1140,1140,1141,1141,171,172,1129,1158,1174,1001,1001,1075,1075,1165,822,1095,1099,1099,1103,1103,888,1073,1073,1087,1094,1098,1098,821,821,1088,1100,1100,969,1066,1067,1067,1069,1069,1071,1071,1092,1092,1673,742,742,950,950,1000,1000,1065,1070,1070,1089,1090,1090,1091,1091,1162,1162,1163,1163,1316,1096,1096,1969,1487,743,743,5741,1074,1076,1068,1093,5743,820,820,1672,1577,1577,1638,1638],["Dostarlimab","Cemiplimab","Avelumab","Durvalumab","Atezolizumab","Nivolumab","Pembrolizumab","Ipilimumab","Cetrelimab","Penpulimab","Sasanlimab","Sintilimab","Balstilimab","Ociperlimab","Quavonlimab","Serplulimab","Sugemalimab","Tiragolumab","Toripalimab","Camrelizumab","Domvanalimab","Erfonrilimab","Erfonrilimab","Pucotenlimab","Retifanlimab","Tislelizumab","Tremelimumab","Vibostolimab","Zimberelimab","Spartalizumab","Bintrafusp Alfa","Bintrafusp Alfa","Bintrafusp Alfa","Bintrafusp Alfa","APL-501","Pacmilimab","Cadonilimab","Cadonilimab","Envafolimab","Pidilizumab","Tebotelimab","Tebotelimab","Zalifrelimab","IBI-939","Etigilimab","Budigalimab","Lodapolimab","Mavorixafor","Milatuzumab","Ciforadenant","Anti-PD-1 Fusion Protein AMP-224","Anti-TIGIT Monoclonal Antibody ASP8374","Anti-TIM3 Monoclonal Antibody LY3321367","Encelimab","Manelimab","Vudalimab","Vudalimab","Izuralimab","Latikafusp","Opucolimab","Reozalimab","Reozalimab","Zigakibart","Acasunlimab","Acasunlimab","Adebrelimab","Alsevalimab","Bapotulimab","Belrestotug","Dargistotug","Favezelimab","Ligufalimab","Lipustobart","Lomvastomig","Ontorpacept","Pavunalimab","Pavunalimab","Porustobart","Prolgolimab","Rulonilimab","Tamgiblimab","Tinurilimab","Tobemstomig","Volrustomig","Zeluvalimab","Danburstotug","Davoceticept","Fidasimtamab","Geptanolimab","Lorigerlimab","Maplirpacept","Miptenalimab","Nofazinlimab","Tagitanlimab","Tuparstobart","Betifisolimab","PD1 Inhibitor","Ralzapastotug","Rilvegostomig","Surzebiclimab","Epacmarstobart","Efprezimod Alfa","PD-L1 Inhibitor","Pradusinstobart","PD-1 Ligand Inhibitor","CTLA-4-targeting Agent","PD-L1 Inhibitor AN4005","PD-L1 Inhibitor ABSK043","PD-L1 Inhibitor GS-4224","A2AR Antagonist EXS21546","Indoximod Prodrug NLG802","Nivolumab/Relatlimab-rmbw","PD-L1 Inhibitor BPI-371153","PD-L1 Inhibitor INCB086550","Anti-HLA-G Antibody TTX-080","Anti-PD1 Monoclonal Antibody","PD-1 Directed Probody CX-188","CD80-Fc Fusion Protein FPT155","Anti-CTLA-4 Probody BMS-986288","Anti-PD-L1 Monoclonal Antibody","Anti-SIRP-alpha Antibody BR105","Anti-TIM-3 Antibody BMS-986258","Autologous Anti-ILT3 CAR-T Cells","CD47/SIRPa Blocking Agent TQB2928","Anti-PD-1 Monoclonal Antibody 609A","Anti-PD-1 Monoclonal Antibody MW11","SIRPa-4-1BBL Fusion Protein DSP107","Anti-CD47 Monoclonal Antibody MIL95","Anti-PD-1 Monoclonal Antibody SG001","Anti-PD-1 Monoclonal Antibody TY101","Anti-PD-L1 Monoclonal Antibody RC98","PD-L1/PD-L2/VISTA Antagonist CA-170","PD-L1/PD-L2/VISTA Antagonist CA-170","PD-L1/PD-L2/VISTA Antagonist CA-170","Vibostolimab/Pembrolizumab MK-7684A","Anti-LAG-3 Monoclonal Antibody HLX26","Anti-PD-1 Monoclonal Antibody Sym021","Anti-PD-1 Monoclonal Antibody SYN125","Anti-PD-L1 Monoclonal Antibody LP002","Anti-TIGIT Monoclonal Antibody AK127","Anti-CD47 Monoclonal Antibody IMC-002","Anti-CD47 Monoclonal Antibody ZL-1201","Anti-CTLA-4 Monoclonal Antibody YH001","Anti-LAG-3 Monoclonal Antibody Sym022","Anti-LAIR1 Monoclonal Antibody NGM438","Anti-PD-1 Monoclonal Antibody BAT1306","Anti-PD-1 Monoclonal Antibody BAT1308","Anti-PD-1 Monoclonal Antibody GNR-051","Anti-PD-1/CD47 Infusion Protein HX009","Anti-PD-1/CD47 Infusion Protein HX009","Anti-PD-L1 Monoclonal Antibody FAZ053","Anti-PD-L1 Monoclonal Antibody GR1405","Anti-PD-L1/IL-15 Fusion Protein KD033","Anti-PVR Monoclonal Antibody NTX-1088","Anti-PVRIG Monoclonal Antibody COM701","Anti-TIGIT Monoclonal Antibody COM902","Anti-TIGIT Monoclonal Antibody TAB006","Anti-TIM-3 Monoclonal Antibody Sym023","Favezelimab/Pembrolizumab Formulation","Favezelimab/Pembrolizumab Formulation","Anti-CD47 Monoclonal Antibody HMPL-A83","Anti-CD47 Monoclonal Antibody STI-6643","Anti-CTLA-4 Monoclonal Antibody ADG116","Anti-CTLA-4 Monoclonal Antibody ADG126","Anti-CTLA-4 Monoclonal Antibody BA3071","Anti-CTLA-4 Monoclonal Antibody IBI310","Anti-CTLA-4 Monoclonal Antibody XTX101","Anti-ICOS Monoclonal Antibody MEDI-570","Anti-LAG-3 Monoclonal Antibody IBI-110","Anti-LAG-3 Monoclonal Antibody LBL-007","Anti-LILRB4 Monoclonal Antibody IO-202","Anti-LILRB4 Monoclonal Antibody NGM831","Anti-PD-1 Monoclonal Antibody MEDI0680","Anti-PD-1 Monoclonal Antibody SHR-1901","Anti-PD-L1 Monoclonal Antibody CBT-502","Anti-TIGIT Monoclonal Antibody BAT6005","Anti-TIGIT Monoclonal Antibody BAT6021","Anti-TIGIT Monoclonal Antibody SGN-TGT","Anti-TIM-3 Monoclonal Antibody TQB2618","Anti-TIM3 Monoclonal Antibody SHR-1702","Adenosine A2A Receptor Antagonist TT-10","Anti-BTN1A1 Monoclonal Antibody hSTC810","Anti-CTLA-4 Monoclonal Antibody ONC-392","Anti-PD-L1 Monoclonal Antibody MDX-1105","Anti-TIGIT Bispecific Antibody AGEN1777","SIRPa-Fc-CD40L Fusion Protein SL-172154","Adenosine A2A Receptor Antagonist CS3005","Adenosine A2A Receptor Antagonist NIR178","Anti-CD96 Monoclonal Antibody GSK6097608","Anti-CTLA-4 Monoclonal Antibody ADU-1604","Anti-CTLA-4 Monoclonal Antibody REGN4659","Anti-OX40 Monoclonal Antibody GSK3174998","Anti-PD-1/TGFbRII Fusion Protein LBL-015","Anti-PD-1/VEGF Bispecific Antibody AK112","Anti-PD-L1/VEGFR-1 Fusion Protein HB0025","Anti-SIRPa Monoclonal Antibody BI 765063","Anti-SIRPa Monoclonal Antibody BI 765063","Anti-SIRPa Monoclonal Antibody BI 770371","Anti-SIRPa Monoclonal Antibody BI 770371","Adenosine A2A Receptor Antagonist DZD2269","Adenosine A2A Receptor Antagonist ILB2109","Anti-PVRIG Monoclonal Antibody GSK4381562","Anti-TIGIT Monoclonal Antibody BMS-986207","Anti-TNFR2 Monoclonal Antibody SIM1811-03","Anti-LAG-3/PD-L1 Bispecific Antibody FS118","Anti-LAG-3/PD-L1 Bispecific Antibody FS118","Anti-PD-1/LAG-3 Bispecific Antibody EMB-02","Anti-PD-1/LAG-3 Bispecific Antibody EMB-02","Anti-TIM-3 Monoclonal Antibody INCAGN02390","Anti-CTLA4 Antibody Fc Fusion Protein KN044","Anti-PD-L1/CD27 Bispecific Antibody CDX-527","Anti-PD-L1/TGFbetaRII Fusion Protein BJ-005","Anti-PD-L1/TGFbetaRII Fusion Protein BJ-005","Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706","Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706","Anti-FOXP3 Antisense Oligonucleotide AZD8701","Anti-PD-1/CTLA-4 Bispecific Antibody SI-B003","Anti-PD-1/CTLA-4 Bispecific Antibody SI-B003","Anti-PD-L1/4-1BB Bispecific Antibody ATG-101","Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","Anti-PD-L1/TGF-beta Bispecific Antibody Y101D","Anti-PD-L1/TGF-beta Bispecific Antibody Y101D","Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105","Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","Anti-HLA-G/CD3 Bispecific Antibody JNJ-78306358","Anti-PD-1/Anti-CD3 Bispecific Antibody ONO-4685","Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","Anti-PD-1/Anti-TIGIT Bispecific Antibody IBI321","Anti-PD-1/Anti-TIGIT Bispecific Antibody IBI321","Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410","Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410","Anti-PD-L1/Anti-OX40 Bispecific Antibody EMB-09","Anti-PD-L1/Anti-OX40 Bispecific Antibody EMB-09","Autologous PD-L1/CD80/CD86-targeted CAR-T Cells","Anti-CD47/Anti-PD-L1 Bispecific Antibody 6MW3211","Anti-CD47/Anti-PD-L1 Bispecific Antibody 6MW3211","Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705","Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705","Anti-LAG-3/Anti-PD-L1 Bispecific Antibody IBI323","Anti-LAG-3/Anti-PD-L1 Bispecific Antibody IBI323","Anti-PD-1/Anti-4-1BB Bispecific Antibody IBI-319","Anti-PD-1/Anti-TIM-3 Bispecific Antibody AZD7789","Anti-PD-1/Anti-TIM-3 Bispecific Antibody AZD7789","Anti-PD-L1/Anti-4-1BB Bispecific Antibody ABL503","Anti-PD-L1/Anti-CD47 Bispecific Antibody BAT7104","Anti-PD-L1/Anti-CD47 Bispecific Antibody BAT7104","Anti-PD-L1/Anti-LAG-3 Bispecific Antibody ABL501","Anti-PD-L1/Anti-LAG-3 Bispecific Antibody ABL501","Anti-TIGIT/Anti-PD-L1 Bispecific Antibody HB0036","Anti-TIGIT/Anti-PD-L1 Bispecific Antibody HB0036","Anti-TIGIT/Anti-PD-L1 Bispecific Antibody HLX301","Anti-TIGIT/Anti-PD-L1 Bispecific Antibody HLX301","Atezolizumab and Recombinant Human Hyaluronidase","Anti-PD-L1/Claudin18.2 Bispecific Antibody Q-1802","Anti-PD-L1/Claudin18.2 Bispecific Antibody Q-1802","Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-101","Autologous Anti-PD-L1-armored Anti-CD22 CAR T Cells","Anti-CD47/Anti-PD-L1 Bispecific Antibody PF-07257876","Anti-CD47/Anti-PD-L1 Bispecific Antibody PF-07257876","PD-1 Targeted IL-15 Mutein Fusion Protein PF-07209960","Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363","Anti-PD-1/TGF-beta RII Bifunctional Fusion Protein JS201","Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868","Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858","PD-1-targeted IL-2 Variant Antibody Fusion Protein RO7284755","Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","Autologous PD-1-targeted Chimeric Switch Receptor-modified T Lymphocytes","Autologous EGFR-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies","Autologous EGFR-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies","Autologous Mesothelin-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies","Autologous Mesothelin-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Protein","Protein","Protein","Protein","Unknown","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Unknown","Antibody","Antibody","Antibody","Small molecule","Antibody","Small molecule","Antibody","Unknown","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody",null,"Antibody","Antibody","Antibody",null,"Antibody","Antibody","Antibody","Antibody","Antibody",null,null,"Antibody","Antibody","Antibody",null,"Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody",null,null,"Antibody",null,"Small molecule","Antibody","Antibody","Antibody","Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Small molecule",null,null,"Antibody","Antibody",null,"Small molecule","Antibody","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule",null,null,"Small molecule","Small molecule","Antibody","Antibody",null,null,"Antibody","Antibody","Antibody","Antibody",null,null,"Antibody","Antibody",null,"Antibody","Antibody","Antibody","Antibody","Small molecule","Small molecule","Small molecule",null,"Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Small molecule","Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody",null,null,"Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Small molecule","Antibody","Antibody","Antibody","Antibody",null,"Small molecule","Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Small molecule","Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Small molecule","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody",null,"Antibody","Antibody",null,null,"Antibody","Antibody",null,"Antibody","Antibody","Antibody","Antibody","Small molecule","Antibody","Antibody","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["PDCD1","PDCD1","CD274","CD274","CD274","PDCD1","PDCD1","CTLA4","PDCD1","PDCD1","PDCD1","PDCD1","PDCD1","TIGIT","CTLA4","PDCD1","CD274","TIGIT","PDCD1","PDCD1","TIGIT","CD274","CTLA4","PDCD1","PDCD1","PDCD1","CTLA4","TIGIT","PDCD1","PDCD1","CD274","TGFB1","TGFB2","TGFB3","PDCD1","CD274","CTLA4","PDCD1","CD274","PDCD1","LAG3","PDCD1","CTLA4","TIGIT","TIGIT","PDCD1","CD274","CXCR4","CD74","ADORA2A","PDCD1","TIGIT","HAVCR2","LAG3","CD274","CTLA4","PDCD1","PDCD1",null,"CD274","CD274","PDCD1",null,"CD274","TNFRSF9","CD274","VTCN1","ILDR2",null,null,"LAG3","CD47","PDCD1",null,"CD47","CTLA4","LAG3","CTLA4","PDCD1","PDCD1","TIGIT","CEACAM6",null,null,"PDCD1",null,"CTLA4","ERBB2","PDCD1","CTLA4","CD47","LAG3","PDCD1","CD274","LAG3","CD274","PDCD1",null,null,"HAVCR2","CD47",null,"CD274","PDCD1","CD274","CTLA4","CD274","CD274","CD274","ADORA2A",null,null,"CD274","CD274","HLA-G","PDCD1",null,null,"CTLA4","CD274","CD47","HAVCR2",null,null,"PDCD1","PDCD1",null,"CD47","PDCD1","PDCD1","CD274","CD274","PDCD1LG2","VSIR",null,"LAG3","PDCD1","PDCD1","CD274","TIGIT","CD47","CD47","CTLA4","LAG3","LAIR1","PDCD1","PDCD1","PDCD1","CD47","PDCD1","CD274","CD274","CD274","TIGIT","PVRIG","TIGIT","TIGIT","HAVCR2","LAG3","PDCD1","CD47","CD47","CTLA4","CTLA4","CTLA4","CTLA4","CTLA4","ICOS","LAG3","LAG3",null,null,"PDCD1","PDCD1","CD274","TIGIT","TIGIT","TIGIT","HAVCR2","HAVCR2","ADORA2A","BTN1A1","CTLA4","CD274","TIGIT",null,"ADORA2A","ADORA2A","CD96","CTLA4","CTLA4","TNFRSF4","PDCD1","PDCD1","CD274","CD47","SIRPA","CD47","SIRPA","ADORA2A","ADORA2A","PVRIG","TIGIT","TNFRSF1B","CD274","LAG3","LAG3","PDCD1","HAVCR2","CTLA4","CD274","CD274","TGFB1","CTLA4","PDCD1","FOXP3","CTLA4","PDCD1","CD274","CD274","CD274","TGFB1","CTLA4","TNFRSF4","CD274","CD274","HAVCR2","HLA-G","PDCD1","CD274","PDCD1","PDCD1","TIGIT","HAVCR2","PDCD1","CD274","TNFRSF4","CTLA4","CD274","CD47","ERBB2","PDCD1","CD274","LAG3","PDCD1","HAVCR2","PDCD1","CD274","CD274","CD47","CD274","LAG3","CD274","TIGIT","CD274","TIGIT",null,"CD274","CLDN18",null,null,"CD274","CD47",null,"PDCD1","PDCD1","PDCD1","CD274","PDCD1","CTLA4","PDCD1","PDCD1","CTLA4","PDCD1","CTLA4","PDCD1"],["programmed cell death 1","programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","CD274 molecule","transforming growth factor beta 1","transforming growth factor beta 2","transforming growth factor beta 3","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","programmed cell death 1","lymphocyte activating 3","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","CD274 molecule","C-X-C motif chemokine receptor 4","CD74 molecule","adenosine A2a receptor","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","hepatitis A virus cellular receptor 2","lymphocyte activating 3","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1",null,"CD274 molecule","CD274 molecule","programmed cell death 1",null,"CD274 molecule","TNF receptor superfamily member 9","CD274 molecule","V-set domain containing T cell activation inhibitor 1","immunoglobulin like domain containing receptor 2",null,null,"lymphocyte activating 3","CD47 molecule","programmed cell death 1",null,"CD47 molecule","cytotoxic T-lymphocyte associated protein 4","lymphocyte activating 3","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","CEA cell adhesion molecule 6",null,null,"programmed cell death 1",null,"cytotoxic T-lymphocyte associated protein 4","erb-b2 receptor tyrosine kinase 2","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","CD47 molecule","lymphocyte activating 3","programmed cell death 1","CD274 molecule","lymphocyte activating 3","CD274 molecule","programmed cell death 1",null,null,"hepatitis A virus cellular receptor 2","CD47 molecule",null,"CD274 molecule","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","CD274 molecule","CD274 molecule","adenosine A2a receptor",null,null,"CD274 molecule","CD274 molecule","major histocompatibility complex, class I, G","programmed cell death 1",null,null,"cytotoxic T-lymphocyte associated protein 4","CD274 molecule","CD47 molecule","hepatitis A virus cellular receptor 2",null,null,"programmed cell death 1","programmed cell death 1",null,"CD47 molecule","programmed cell death 1","programmed cell death 1","CD274 molecule","CD274 molecule","programmed cell death 1 ligand 2","V-set immunoregulatory receptor",null,"lymphocyte activating 3","programmed cell death 1","programmed cell death 1","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","CD47 molecule","CD47 molecule","cytotoxic T-lymphocyte associated protein 4","lymphocyte activating 3","leukocyte associated immunoglobulin like receptor 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","CD47 molecule","programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","PVR related immunoglobulin domain containing","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","hepatitis A virus cellular receptor 2","lymphocyte activating 3","programmed cell death 1","CD47 molecule","CD47 molecule","cytotoxic T-lymphocyte associated protein 4","cytotoxic T-lymphocyte associated protein 4","cytotoxic T-lymphocyte associated protein 4","cytotoxic T-lymphocyte associated protein 4","cytotoxic T-lymphocyte associated protein 4","inducible T cell costimulator","lymphocyte activating 3","lymphocyte activating 3",null,null,"programmed cell death 1","programmed cell death 1","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","hepatitis A virus cellular receptor 2","hepatitis A virus cellular receptor 2","adenosine A2a receptor","butyrophilin subfamily 1 member A1","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains",null,"adenosine A2a receptor","adenosine A2a receptor","CD96 molecule","cytotoxic T-lymphocyte associated protein 4","cytotoxic T-lymphocyte associated protein 4","TNF receptor superfamily member 4","programmed cell death 1","programmed cell death 1","CD274 molecule","CD47 molecule","signal regulatory protein alpha","CD47 molecule","signal regulatory protein alpha","adenosine A2a receptor","adenosine A2a receptor","PVR related immunoglobulin domain containing","T cell immunoreceptor with Ig and ITIM domains","TNF receptor superfamily member 1B","CD274 molecule","lymphocyte activating 3","lymphocyte activating 3","programmed cell death 1","hepatitis A virus cellular receptor 2","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","CD274 molecule","transforming growth factor beta 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","forkhead box P3","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","transforming growth factor beta 1","cytotoxic T-lymphocyte associated protein 4","TNF receptor superfamily member 4","CD274 molecule","CD274 molecule","hepatitis A virus cellular receptor 2","major histocompatibility complex, class I, G","programmed cell death 1","CD274 molecule","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","hepatitis A virus cellular receptor 2","programmed cell death 1","CD274 molecule","TNF receptor superfamily member 4","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","CD47 molecule","erb-b2 receptor tyrosine kinase 2","programmed cell death 1","CD274 molecule","lymphocyte activating 3","programmed cell death 1","hepatitis A virus cellular receptor 2","programmed cell death 1","CD274 molecule","CD274 molecule","CD47 molecule","CD274 molecule","lymphocyte activating 3","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains",null,"CD274 molecule","claudin 18",null,null,"CD274 molecule","CD47 molecule",null,"programmed cell death 1","programmed cell death 1","programmed cell death 1","CD274 molecule","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1"],["CHEMBL4298124","CHEMBL4297723","CHEMBL3833373","CHEMBL3301587","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL1789844","CHEMBL4298001","CHEMBL4297571","CHEMBL4298191","CHEMBL4297829","CHEMBL4297877","CHEMBL4650411","CHEMBL4650419","CHEMBL4594550","CHEMBL4594535","CHEMBL4298050","CHEMBL4297843","CHEMBL4297715","CHEMBL4650392","CHEMBL4650483","CHEMBL4650483","CHEMBL4650472","CHEMBL4298037","CHEMBL4297840","CHEMBL2108658","CHEMBL4297785","CHEMBL4297856","CHEMBL4297831","CHEMBL4298024","CHEMBL4298024","CHEMBL4298024","CHEMBL4298024","CHEMBL4594355","CHEMBL4297563","CHEMBL4594456","CHEMBL4594456","CHEMBL4298006","CHEMBL2108680","CHEMBL4594578","CHEMBL4594578","CHEMBL4297876","CHEMBL4650473","CHEMBL4298205","CHEMBL4297858","CHEMBL4298020","CHEMBL518924","CHEMBL1743040","CHEMBL4297184","CHEMBL4297570","CHEMBL4297894","CHEMBL4298022",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"CHEMBL4298114",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"CHEMBL2109449",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"CHEMBL4297702",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["ANTAGONIST","INHIBITOR","OTHER","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","ANTAGONIST","BINDING AGENT","INHIBITOR","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","BINDING AGENT","BINDING AGENT","BINDING AGENT","BINDING AGENT","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","NA","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","ANTAGONIST","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","NA","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","NA","NA","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","NA","A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","NA","NA","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","NA","NA","A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","NA","A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.","A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.","A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.","A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells.","A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","A humanized, Fc-engineered bispecific monoclonal antibody directed against both the human negative immunoregulatory checkpoint receptor, programmed cell death protein 1 (PD-1; PCD-1; CD279), and inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, izuralimab targets and binds to both PD-1 and ICOS expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs). This prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), and stimulates ICOS-mediated signaling, which promotes the activation of T-cells and enhances T-cell-mediated immune responses against tumor cells. Combined PD-1 blockade and ICOS stimulation may enhance T-cell activation and proliferation more than targeting each receptor individually. The engineered Fc domain increases the stability and half-life of the antibody.","An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of latikafusp, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.","A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.","A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.","A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.","A human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and anti-tumor activities. Upon administration, belrestotug targets and binds to TIGIT expressed on various immune cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. In addition, belrestotug may preferentially deplete immunosuppressive, TIGIT-expressing regulatory T-cells (Tregs) through Fc gamma receptor interaction and antibody-dependent cellular cytotoxicity (ADCC). This may further enhance anti-tumor activity. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","An inhibitor of T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), a co-inhibitory molecule and immune checkpoint inhibitor, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dargistotug targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ligufalimab targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.","A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, porustobart targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. In addition, porustobart induces an antibody-dependent cell cytotoxicity (ADCC). CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. Porustobart, being a HCAb, is smaller than conventional antibodies which may allow for increased tissue penetration.","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A recombinant human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tamgiblimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,tinurilimab targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tobemstomig targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.","An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, volrustomig is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with volrustomig may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.","A human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zeluvalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, danburstotug specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, anti-PD-L1 monoclonal antibody IMC-001 also induces antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A fusion protein composed of the N-terminal Ig variable-like (IgV) domain of CD80 fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, davoceticept targets and binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, which blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), and leads to PD-L1-dependent CD28 binding and co-stimulation in the local tumor microenvironment (TME). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling, leads to the co-stimulation of T-cell responses including the activation of na\u001a\u001ave and memory T-cells in the TME and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, davoceticept targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation. This further promotes T-cell activity. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","An immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PD1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, geptanolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.","A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.","A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","A FcR-enabled immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, ralzapastotug targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, rilvegostomig simultaneously targets, binds to and inhibits PD-1 and TIGIT and their downstream signaling pathways. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","An antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, epacmarstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","A recombinant fusion protein composed of the extracellular domain of the mature human glycoprotein CD24 linked to a human immunoglobulin G1 (IgG1) Fc domain, with potential immune checkpoint inhibitory, anti-inflammatory and antineoplastic activities. Upon administration, efprezimod alfa binds to injured cell components, also called DAMPs (Danger-Associated Molecular Patterns), thereby preventing the interaction of DAMPs with toll-like receptors (TLRs) and inhibiting both nuclear factor-kappa B (NFkB) activation and secretion of inflammatory cytokines. In addition, efprezimod alfa binds to and activates Siglec G/10, a sialic acid-binding immunoglobulin-type lectin, and stimulates SHP-1-mediated inhibitory signaling, while also preventing NFkB activation and secretion of inflammatory mediators, which further prevents inflammatory responses. DAMPs activate the innate immune system. CD24 binds to both DAMPs and Siglec G/10 to regulate immune responses.CD24/Siglec G/10 interaction plays a key role in a number of immune-mediated diseases including graft-versus-host disease (GvHD), multiple sclerosis and rheumatoid arthritis.","An agent designed to interfere with the activity of programmed death ligand 1 (PD-L1; CD274), a ligand for the receptor programmed cell death protein 1 (PD-1; PD1).","A humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pradusinstobart targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273).","Any agent that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; CTLA4; CD152).","An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, PD-L1 inhibitor AN4005 specifically targets and binds to PD-L1 expressed on tumor cells, thereby preventing the binding of PD-L1 to and subsequent activation of its receptor programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, PD-L1 inhibitor ABSK043 specifically targets and binds to PD-L1 expressed on tumor cells, leading to internalization and preventing the binding to and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, PD-L1 inhibitor GS-4224 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.","An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist EXS21546 selectively targets, binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression in the tumor microenvironment (TME). EXS21546 does not penetrate the central nervous system (CNS).","An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.","An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T-lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","An orally bioavailable, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, PD-L1 inhibitor BPI-371153 specifically targets and binds to PD-L1 expressed on tumor cells, thereby preventing the binding to and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.","A monoclonal antibody directed against programmed cell death protein 1 (PD-1; PD1; CD279).","A probody composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a proprietary masking peptide that covers the active antigen binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of PD-1-directed probody CX-188, the masking peptide is cleaved by tumor-associated proteases within the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to PD-1, thereby disrupting PD-1 signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation of T-cell responses including the activation of na\u001a\u001ave and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","A probody composed of a modified version of ipilimumab, a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 probody BMS-986288, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986288 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","A monoclonal antibody directed against programmed death-ligand 1 (PD-L1; CD274).","An antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-SIRPa antibody BR105 targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the immune inhibitory receptor leukocyte immunoglobulin-like receptor B member 4 (LILRB4; ILT3; ILT-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, autologous anti-ILT3 CAR-T cells target and bind to ILT3-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against ILT3-expressing tumor cells. ILT3, a tumor associated antigen (TAA) and an immune inhibitory receptor expressed on immune suppressive myeloid cells, is highly expressed on certain hematologic cancer cells, such as monocytic acute myeloid leukemia (AML) cells. It functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration, T-cell suppression and immune tolerance.","An agent blocking the interaction between the leukocyte surface antigen CD47 and the signal regulatory protein alpha (SIRPalpha; SIRPa), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, CD47/SIRPa blocking agent TQB2928 blocks the interaction between CD47, which is expressed on tumor cells, and SIRPa, which is expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody 609A targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A recombinant humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MW11 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A bi-functional, trimeric, fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) fused to a 4-1BB ligand (4-1BBL), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, the SIRPa-4-1BBL fusion protein DSP107 selectively targets and binds to both CD47 expressed on tumor cells and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) expressed on T-cells and natural killer (NK) cells. Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of 4-1BBL to 4-1BB activates 4-1BB-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as NK-mediated tumor cell killing. The crosslinking specifically enables the activation of 4-1BB-mediated signaling in T-cells and NK cells in the tumor microenvironment (TME), allowing targeted immune responses in the TME. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A humanized monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody MIL95 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SG001 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody TY101 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody RC98 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","A co-formulated product containing fixed doses of the two monoclonal antibodies vibostolimab and pembrolizumab, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of vibostolimab/pembrolizumab MK-7684A, vibostolimab, an antibody against the immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT plays a key role in the suppression of T-cell proliferation and activation and tumor cell immune evasion. Pembrolizumab, an antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) targets and binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody HLX26 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SYN125 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody LP002 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, by binding to PD-L1, LP002 also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody AK127 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs.","A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody ZL-1201 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","A recombinant, humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody YH001 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A recombinant, human Fc-inert monoclonal antibody targeting lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody Sym022 binds to human LAG-3 and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHCII) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHCII binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Additionally, Sym022 decreases LAG-3 surface levels through internalization and shredding. LAG-3 plays a key role in the activation of T-cells and natural killer (NK) cells.","A monoclonal antibody directed against the collagen-binding immune inhibitory receptor leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAIR1 monoclonal antibody NGM438 targets, binds to and blocks LAIR1, thereby preventing its interaction with tumor-associated and stromal-derived collagens and the formation of the stromal checkpoint LAIR1-collagen complex. This may inhibit LAIR1-collagen complex-mediated downstream signaling pathways and abrogates LAIR1-collagen complex-mediated myeloid cell immune suppression and inhibition of antitumor immunity. This may also inhibit the physical exclusion of immune cells from the tumor by the LAIR1-collagen complex and enhance T-cell infiltration of the tumor. LAIR1, an immune inhibitory receptor expressed on immune cells and upregulated in various cancers along with stromal-derived collagens, plays an important role in tumor infiltration, immunosuppression and immune tolerance.","A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A humanized  immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1308 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody GNR-051 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 infusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 infusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","A fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to the immunostimulatory cytokine interleukin-15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration of the anti-PD-L1/IL-15 fusion protein KD033, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, IL-15 stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the TME, which induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","An immunoglobulin G4 (IgG4) monoclonal antibody targeting the poliovirus receptor (PVR; CD155; nectin-like protein 5; NECL-5), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PVR monoclonal antibody NTX-1088 targets and binds to PVR expressed on tumor cells, thereby preventing its interactions with the human cell surface glycoprotein CD226 (DNAX accessory molecule-1; DNAM-1), the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression). The binding of NTX-1088 to CD226 prevents the internalization of CD226 and restores its expression on the surface of immune cells. This promotes CD226-dependent signaling pathways, which may trigger the activation of antigen-presenting cells (APCs) and activate T-cells and natural killer (NK) cells, and result in an enhanced cytotoxic T-lymphocyte (CTL)-mediated and NK cell-mediated immune response against tumor cells. The binding of NTX-1088 to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands and promotes the interaction of its ligands with the costimulatory receptor CD226 expressed on immune cells. This leads to CD226 dimerization and further promotes CD226-mediated signaling and anti-tumor immune responses. The binding of NTX-1088 to CD96 expressed primarily on T-cells and NK cells prevents its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may further restore immune function and anti-tumor immune responses through the activation of T-cells and NK cells. PVR, a key regulator of immune activation through multiple mechanisms, is overexpressed in a variety of tumor cell types while minimally or not expressed in normal tissues.","A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.","A fully human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody COM902 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody TAB006 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody Sym023 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","A coformulation containing favezelimab, a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), and pembrolizumab, a humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of the favezelimab/pembrolizumab formulation, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T-cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells LAG3, a member of the immunoglobulin superfamily (IgSF) expressed on various immune cells, negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A coformulation containing favezelimab, a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), and pembrolizumab, a humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of the favezelimab/pembrolizumab formulation, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T-cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells LAG3, a member of the immunoglobulin superfamily (IgSF) expressed on various immune cells, negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody HMPL-A83 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","A human monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody STI-6643 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) but is overexpressed on the surface of a variety of cancer cells and contributes to poor prognosis. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. Compared to other anti-CD47 monoclonal antibodies, STI-6643 shows decreased binding to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs. In addition, STI-6643 has a minimal effect on T-, B- or natural killer (NK) cell depletion which may further improve its efficacy by preserving infiltrating anti-tumor immune cells.","A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADG116 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A human monoclonal antibody with a masked antibody binding site directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration and the activation of the antibody binding site in the tumor microenvironment (TME), anti-CTLA-4 monoclonal antibody ADG126 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A conditionally active biologic (CAB) and monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration and specific activation in the tumor microenvironment (TME) due to the unique microphysical conditions that are present in the TME, anti-CTLA-4 monoclonal antibody BA3071 targets and binds to CTLA-4 expressed on T-cells within the TME and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. By using a CAB anti-CTLA-4 antibody, systemic toxicity may be reduced.","A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody IBI310 targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A fully humanized, Fc-engineered monoclonal antibody with masked antigen-binding regions directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration and the activation of the antigen-binding regions via cleavage by proteases that are upregulated in the tumor microenvironment (TME), anti-CTLA-4 monoclonal antibody XTX101 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.","A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody IBI110 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody LBL-007 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","A monoclonal antibody directed against the immune inhibitory receptor leukocyte immunoglobulin-like receptor B4 (LILRB4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody IO-202 targets, binds to and inhibits LILRB4 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells, and inhibit tumor infiltration. LILRB4, an immune inhibitory receptor normally expressed on monocytic cells and highly expressed on monocytic acute myeloid leukemia (AML) cells, functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration in leukemias through multiple signaling pathways.","A monoclonal antibody directed against the myeloid-enriched immune inhibitory receptor leukocyte immunoglobulin-like receptor B member 4 (LILRB4; ILT3; ILT-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody NGM831 targets, binds to and blocks LILRB4, thereby preventing the interaction with its ligands, such as fibronectin, in the tumor microenvironment (TME). This prevents the activation of LILRB4-mediated downstream signaling pathways. This may abrogate LILRB4-mediated promotion of myeloid cell immunosuppression and inhibition of antitumor immunity. This may restore immune function by activating dendritic cells (DCs) and T-cells, and may promote T-cell-mediated immune responses against tumor cells. LILRB4, an inhibitory immune receptor highly expressed on tumor-associated myeloid cells, primarily tolerogenic DCs, myeloid-derived suppressor cells (MDSCs) and M2 macrophages, functions as an immune checkpoint that negatively regulates DC- and T-cell activation. It is upregulated in several tumor types and plays an important role in tumor infiltration, immunosuppression and immune tolerance.","A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1901 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2). PD-1 plays an important role in tumor evasion from host immunity.","A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody CBT-502 specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","An immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody BAT6005 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A recombinant humanized monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody BAT6021 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A nonfucosylated human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody SGN-TGT targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs). This prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), and enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This enhances depletion of TIGIT-positive regulatory T-cells (Tregs) and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIM-3 monoclonal antibody TQB2618 targets and binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIM3 monoclonal antibody SHR-1702 targets and binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist TT-10 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","A humanized monoclonal antibody directed against the immune checkpoint protein butyrophilin 1A1 (BTN1A1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti- BTN1A1 monoclonal antibody hSTC810 targets and binds to the extracellular domain of human BTN1A1, which prevents the formation of the BTN1A1-galectin-9 (Gal9)-programmed cell death protein 1 (PD-1) complex, and inhibits downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The BTN1A1-Gal9-PD-1 axis suppresses T-cell receptor (TCR) signaling and T-cell activation. BTN1A1 does not bind to PD-1 directly but interacts with PD-1 through Gal9. BTN1A1, a member of the butyrophilin superfamily of immunomodulators, is upregulated in a variety of tumor cell types.","A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody ONC-392 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As ONC-392 is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","A Fc-enhanced bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and an as of yet undisclosed receptor expressed specifically on T-cells and natural killer (NK) cells, with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration, the anti-TIGIT bispecific antibody AGEN1777 simultaneously targets and binds to TIGIT and the undisclosed receptor. Upon binding to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), AGEN1777 blocks the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. In addition, binding of AGEN1777 to the undisclosed target expressed on T-cells and NK cells may further enhance anti-tumor immune responses. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A bi-functional fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) and CD40 ligand (CD40L; CD154; TRAP; TNFSF5) linked via a human Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the SIRPa-Fc-CD40L fusion protein SL-172154 selectively targets and binds to both CD47 expressed on tumor cells and CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family, expressed on antigen-presenting cells (APCs). Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of CD40L to CD40 activates CD40, increases CD40-mediated signaling and induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived dendritic cells (moDCs), and leads to the secretion of inflammatory cytokines. This activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. The crosslinking specifically enhances antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist CS3005 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD96 monoclonal antibody GSK6097608 targets, binds to and inhibits CD96 expressed primarily on T-cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T-cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T-cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings.","A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","A tetravalent bispecific fusion protein targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint modulating and antineoplastic activities. Upon administration, anti-PD-1/TGF-beta receptor II (TGFbRII) fusion protein LBL-015 targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates the PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocyte; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.","A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration of anti-PD-1/VEGF bispecific antibody AK112, this agent simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF. The binding of AK112 to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and/or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of AK112 to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1/ or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.","A recombinant, humanized fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1), with potential anti-angiogenesis, immune checkpoint inhibitory and antineoplastic activities. Upon administration of the anti-PD-L1/VEGFR-1 fusion protein HB0025, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, VEGFR-1 moiety binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to the endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis and metastasis, and ultimately tumor regression. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","An immunoglobulin G4 (IgG4) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody BI 765063 targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","An immunoglobulin G4 (IgG4) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody BI 765063 targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","An immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody BI 770371 targets and binds to SIRPa expressed on myeloid cells, including monocytes, macrophages, dendritic cells (DCs), and neutrophils, thereby blocking the interaction between SIRPa and its ligand cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis and the CD47/SIRPa-mediated suppression of the innate immune response. This induces pro-phagocytic signaling and the specific phagocytosis of tumor cells, and restores immune responses mediated by myeloid cells in the tumor microenvironment (TME). SIRPa, an innate immune checkpoint receptor expressed primarily on myeloid cells and neurons that is also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and DC activation. CD47, also known as integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of phagocytosis and the suppression of innate immunity, which allows cancer cells to proliferate. BI 770371 binds to both the V1 and V2 variants of SIRPa.","An immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody BI 770371 targets and binds to SIRPa expressed on myeloid cells, including monocytes, macrophages, dendritic cells (DCs), and neutrophils, thereby blocking the interaction between SIRPa and its ligand cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis and the CD47/SIRPa-mediated suppression of the innate immune response. This induces pro-phagocytic signaling and the specific phagocytosis of tumor cells, and restores immune responses mediated by myeloid cells in the tumor microenvironment (TME). SIRPa, an innate immune checkpoint receptor expressed primarily on myeloid cells and neurons that is also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and DC activation. CD47, also known as integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of phagocytosis and the suppression of innate immunity, which allows cancer cells to proliferate. BI 770371 binds to both the V1 and V2 variants of SIRPa.","An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist DZD2269 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist ILB2109 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody GSK4381562 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME), thereby blocking the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. This abrogates the PVRIG-mediated inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and an immune checkpoint receptor, negatively regulates the activation of various immune cells upon activation and plays a key role in immunosuppression.","A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody BMS-986207 binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against tumor necrosis factor receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities Upon administration, anti-TNFR2 monoclonal antibody SIM1811-03 targets and binds to TNFR2 expressed on immune suppressive cells, such as tumor-associated regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and depletes these TNFR2-expressing immune suppressive cells. Also, SIM1811-03 prevents the activation of TNFR2 by endogenous tumor necrosis factor (TNF) and TNFR2-mediated signaling, blocks the activation of the nuclear factor kappa B (NF-kB) signaling pathway, halts TNFR2-mediated immunosuppression, thereby inhibiting the proliferation and function of Tregs and enhancing cytotoxic T-cell-mediated anti-tumor immune responses. In addition, SIM0235 is able to bind to TNFR2 expressed on the surface of tumor cells, thereby killing TNFR2-expressing tumor cells directly. TNFR2, a member of the TNFR family of co-stimulatory molecules, plays a role in tumor necrosis factor signaling, tumor expansion and survival. It is primarily expressed on the surface of tumor cells and suppressive immune cells in the TME, but rarely in normal human tissues or peripheral immune cells.","A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/LAG-3 bispecific antibody EMB-02 targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/LAG-3 bispecific antibody EMB-02 targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.","A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, INCAGN02390 forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.","A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","A bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the cell surface antigen CD27, with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/CD27 bispecific antibody CDX-527 targets and binds to both PD-L1 expressed on tumor cells and CD27 expressed on a variety of immune cell types, including most T-lymphocytes. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling and induces CD27-mediated signaling. This inhibits the PD-1-mediated downregulation of T-cell activation and proliferation, and enhances CD27-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation.","A recombinant bifunctional fusion protein composed of a humanized immunoglobulin (Ig) G1 anti-programmed death ligand 1 (PD-L1) monoclonal antibody fused to the extracellular domain (ECD) of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein BJ-005, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the antibody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A recombinant bifunctional fusion protein composed of a humanized immunoglobulin (Ig) G1 anti-programmed death ligand 1 (PD-L1) monoclonal antibody fused to the extracellular domain (ECD) of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein BJ-005, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the antibody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A mixture of two engineered monoclonal antibodies produced by a single cell line of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/anti-CTLA4 antibody mixture QL1706 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A mixture of two engineered monoclonal antibodies produced by a single cell line of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/anti-CTLA4 antibody mixture QL1706 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","An antisense oligonucleotide (ASO) targeting the Forkhead Box P3 (FOXP3) mRNA, with potential immunomodulating and antineoplastic activities. Upon administration, anti-FOXP3 ASO AZD8701 blocks the translation of the FOXP3 protein. Reduction of FOXP3 levels may lessen the immunosuppressive functions of regulatory T-cells (Tregs). This may lead to an enhanced immune response and antitumor activity. FOXP3, a transcription factor, plays an important role in the functioning of immunosuppressive Tregs. Tregs are overexpressed in various cancers and are associated with poor response to immune checkpoint inhibitors and poor survival.","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/CTLA4 bispecific antibody SI-B003 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with SI-B003 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/CTLA4 bispecific antibody SI-B003 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with SI-B003 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A bispecific antibody composed of a human immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1 (PD-L1) fused with a single chain variable fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB bispecific antibody ATG-101 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Upon PD-L1 binding, the 4-1BB activation signal is induced and ATG-101 acts as a conditional 4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, ATG-101 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.","A recombinant bispecific antibody targeting both the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the human transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A recombinant bispecific antibody targeting both the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the human transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.","A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.","A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB bispecific antibody INBRX-105 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, INBRX-105 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, INBRX-105 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody targeting the tumor-associated antigen (TAA) HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T-lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody JNJ-78306358 targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion. It inhibits immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs).","A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the T-cell surface antigen CD3, with potential immunomodulatory and antineoplastic activities. Upon administration, anti-PD-1/anti-CD3 bispecific antibody ONO-4685 binds to both PD-1 expressed on activated T- and B-cells and certain malignant T-cells and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This may activate and redirect CTLs to PD-1-expressing cells, resulting in CTL-mediated killing of these cells. This may lead to anti-tumor activity in some T-cell lymphomas, and immunomodulatory activity in some autoimmune diseases.","A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-PD-1/anti-TIGIT bispecific antibody IBI321 simultaneously targets, binds to and inhibits PD-1 and TIGIT and their downstream signaling pathways. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-PD-1/anti-TIGIT bispecific antibody IBI321 simultaneously targets, binds to and inhibits PD-1 and TIGIT and their downstream signaling pathways. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A tetravalent, bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274) and the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/anti-OX40 bispecific antibody EMB-09 binds to PD-L1 expressed on tumor cells, and simultaneously binds to and activates OX40 on activated T-cells. The binding of EMB-09 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. The binding of EMB-09 to OX40 and the activation of OX40 induces the proliferation of memory and effector T-lymphocytes, which also enhances the anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is mainly expressed on activated T-cells and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","A tetravalent, bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274) and the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/anti-OX40 bispecific antibody EMB-09 binds to PD-L1 expressed on tumor cells, and simultaneously binds to and activates OX40 on activated T-cells. The binding of EMB-09 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. The binding of EMB-09 to OX40 and the activation of OX40 induces the proliferation of memory and effector T-lymphocytes, which also enhances the anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is mainly expressed on activated T-cells and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","A preparation of autologous human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a modified from of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1), in which the intracellular signal domain of PD-1 is transformed to allow for stimulatory signaling but with an intact extracellular ligand binding domain that specifically binds the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), and a modified form of the T-cell inhibitory receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with a transformed intracellular signal domain to allow for stimulatory signaling, which specifically binds the B7 proteins CD80 (B7-1) and CD86 (B7-2), with potential immunostimulating and antineoplastic activities. Usually, ligand binding to PD-1 and CTLA-4 inhibits T-cell activity; however, these modified forms of PD-1 and CTLA-4 promote T-cell stimulatory signaling. Upon administration, the autologous PD-L1/CD80/CD86-targeted CAR-T cells target and bind to PD-L1 expressed on certain tumor cells and to CD80/CD86 expressed on antigen-presenting cells (APCs). This stimulates T-cell activation, T-cell proliferation and enhanced cytokine production, which induces selective toxicity in tumor cells expressing PD-L1. PD-1, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PD-L1 is often overexpressed on tumor cell types and plays a key role in immune evasion. The co-stimulatory molecules CD80 and CD86 play a key role in T-lymphocyte activation upon binding to CD28 upon antigen recognition; however, binding of CD80 and CD86 to wild-type CTLA-4 inhibits T-cell activity and results in T-cell exhaustion.","A humanized bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody 6MW3211 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by 6MW3211 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of 6MW3211 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, 6MW3211 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A humanized bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody 6MW3211 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by 6MW3211 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of 6MW3211 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, 6MW3211 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-HER2/anti-PD-1 bispecific antibody SSGJ-705 simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-HER2/anti-PD-1 bispecific antibody SSGJ-705 simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A recombinant, bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3/anti-PD-L1 bispecific antibody IBI323 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A recombinant, bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3/anti-PD-L1 bispecific antibody IBI323 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-4-1BB bispecific antibody IBI-319 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and 4-1BB, which is expressed on activated T-lymphocytes and natural killer (NK) cells. This crosslinks PD-1- and 4-1BB-expressing T cells. Through 4-1BB binding, IBI-319 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, PD-1 binding prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody AZD7789 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody AZD7789 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A bispecific antibody composed of a Fc-silenced human immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1 (PD-L1) fused with a single chain variable fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/anti-4-1BB bispecific antibody ABL503 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Upon PD-L1 binding, the 4-1BB activation signal is induced and ABL503 acts as a conditional 4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, ABL503 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","A symmetric immunoglobulin G (IgG)-like bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-PD-L1/anti-CD47 bispecific antibody BAT7104 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by BAT7104 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of BAT7104 to PD-L1 blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows cancer cells to proliferate. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. By co-targeting CD47 and PD-L1, BAT7104 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A symmetric immunoglobulin G (IgG)-like bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-PD-L1/anti-CD47 bispecific antibody BAT7104 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by BAT7104 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of BAT7104 to PD-L1 blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows cancer cells to proliferate. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. By co-targeting CD47 and PD-L1, BAT7104 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A bispecific antibody directed against two immune checkpoint proteins composed of an engineered immunoglobulin G4 (IgG4) monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) fused with a single chain variable fragment (scFv) targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1/anti-LAG-3 bispecific antibody ABL501 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression.","A bispecific antibody directed against two immune checkpoint proteins composed of an engineered immunoglobulin G4 (IgG4) monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) fused with a single chain variable fragment (scFv) targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1/anti-LAG-3 bispecific antibody ABL501 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression.","A bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIGIT/anti-PD-L1 bispecific antibody HB0036 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIGIT/anti-PD-L1 bispecific antibody HB0036 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIGIT/anti-PD-L1 bispecific antibody HLX301 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIGIT/anti-PD-L1 bispecific antibody HLX301 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","A co-formulation composed of atezolizumab, a humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), and a recombinant form of human hyaluronidase (rHuPH20), with potential immune checkpoint inhibitory and antineoplastic activities. Upon subcutaneous administration of atezolizumab and hyaluronidase, atezolizumab targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T-cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Hyaluronidase hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of atezolizumab through the interstitial space. This facilitates the delivery of atezolizumab to PD-L1-expressing tumor cells.","A bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/Claudin18.2 bispecific antibody Q-1802 targets and simultaneously binds to both PD-L1 and CLDN18.2 expressed on certain types of tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against CLDN18.2-expressing tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","A bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/Claudin18.2 bispecific antibody Q-1802 targets and simultaneously binds to both PD-L1 and CLDN18.2 expressed on certain types of tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against CLDN18.2-expressing tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","A bi-specific Fc fusion protein composed of the N-terminal extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G4 (IgG4) Fc fragment and linked to an interleukin (IL)-2 variant (IL-2v) as a C-terminal moiety, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of bispecific CD80-IgG4Fc-IL-2v fusion protein GI-101, the CD80 moiety targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, enables the binding of CD80 to CD28, which leads to CD28-mediated signaling, and results in the activation of T-cells in the tumor microenvironment (TME). This promotes T-cell activity. The IL-2 moiety may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. This may enhance the activity of neoantigen specific T-cells and potentiates the T-cell-mediated immune response against tumor cells. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).","A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) CD22 and carrying a single-chain variable fragment (scFv) of a monoclonal antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunomodulatory and antineoplastic activities. Upon infusion, the autologous anti-PD-L1-armored anti-CD22 CAR T cells target and bind to CD22-expressing tumor cells, thereby inducing selective toxicity in CD22-expressing tumor cells. The scFv moiety binds to PD-L1, blocking the binding of PD-L1 to its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), thereby preventing PD-1 activation on T-lymphocytes. This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types and plays a key role in the downregulation of the immune system and tumor evasion from host immunity. PD-1, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","A bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody PF-07257876 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by PF-07257876 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of PF-07257876 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, PF-07257876 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody PF-07257876 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by PF-07257876 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of PF-07257876 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, PF-07257876 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).","A fusion protein composed of a moiety targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-15 (IL-15), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of PD-1 targeted IL-15 mutein fusion protein PF-07209960, the PD-1 targeting moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-15 mutein moiety binds to the IL-15 receptor and activates IL-15 cytokine signaling. This stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the tumor microenvironment (TME), and induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.","A bispecific antibody fusion protein composed of a monoclonal antibody targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and fused to a mutated form of the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/IL-2 bispecific antibody fusion protein IBI363 targets and binds to PD-1 expressed on PD-1-expressing T-cells, thereby inhibiting PD-1-mediated signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. IL-2 targets and binds to the IL-2 receptor IL2R and activates IL-2/IL-2R-mediated signaling, which further activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This further enhances T-cell-mediated cytotoxic immune responses against tumor cells. By selectively activating PD-1 positive T-cells by IL-2, but not PD-1 negative bystander or na\u001a\u001ave T cells, the activity of tumor specific T-cells is specifically enhanced while IL-2-induced systemic toxicity is decreased. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A bifunctional fusion protein targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint modulating, immunomodulating and antineoplastic activities. Upon administration, anti-PD-1/TGF-beta RII bifunctional fusion protein JS201 targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates the PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression and the suppression of the immune response.","A bifunctional fusion protein directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TGF-beta bifunctional fusion protein TQB2868  targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.","A bifunctional fusion protein directed against both human programmed death ligand 1 (PD-L1) and transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858 targets, binds to and neutralizes TGF-beta on tumor cells and simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cells. This prevents both TGF-beta- and PD-L1-mediated immunosuppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This also restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A recombinant fusion protein comprised of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of PD-1-targeted IL-2v antibody fusion protein RO7284755, the antibody moiety specifically targets and binds to PD-1 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. The IL-2 moiety may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. This may enhance the activity of neoantigen specific T-cells and potentiates T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).","A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","Autologous human T-lymphocytes that are genetically engineered to express a chimeric switch receptor (CSR) composed of the extracellular ligand binding domain of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1) fused to the transmembrane and cytoplasmic co-stimulatory signaling domains of CD28 (PD1CD28; PD-1:CD28 switch receptor), with potential immunomodulating and antineoplastic activities. Upon reintroduction of autologous PD-1-targeted CSR-modified T-lymphocytes into the patient, the switch receptor expressed by the engineered T-cells targets and binds to the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2) expressed, on tumor cells. The nature of the PD-1/CD28 switch receptor fusion protein prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This induces enhanced toxicity against PD-L1-expressing tumor cells. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. Exchanging the transmembrane and intracellular domain of PD-1 with that of CD28 converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28, is a molecule expressed by T-cells that stimulates increased T-lymphocyte proliferation and activity.","A preparation of autologous T-lymphocytes that have been activated and genetically modified to express immune checkpoint antibodies against the negative immunoregulatory receptors human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating and antineoplastic activities. After isolation, activation, transduction, expansion in culture and reintroduction into the patient, the T-cells in the autologous EGFR specific CAR-T-cells expressing anti-PD-1/CTLA4 antibodies  specifically target and kill EGFR-expressing tumor cells. The anti-PD-1 antibody secreted from the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion. The anti-CTLA4 expressed by the CAR-T cells targets and binds to CTLA4 expressed on T-cells, and inhibits the CTLA4-mediated downregulation of T-cell activation. Both antibodies enhance T-cell activation, improve immunosuppression in the tumor microenvironment (TME) and improve the T-cell mediated immune response against and toxicity in EGFR-expressing tumor cells. Both PD-1 and CTLA-4 negatively regulate T-cell activation and proliferation, and play a key role in immunosuppression within the TME. EGFR, a receptor tyrosine kinase that is overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation.","A preparation of autologous T-lymphocytes that have been activated and genetically modified to express immune checkpoint antibodies against the negative immunoregulatory receptors human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating and antineoplastic activities. After isolation, activation, transduction, expansion in culture and reintroduction into the patient, the T-cells in the autologous EGFR specific CAR-T-cells expressing anti-PD-1/CTLA4 antibodies  specifically target and kill EGFR-expressing tumor cells. The anti-PD-1 antibody secreted from the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion. The anti-CTLA4 expressed by the CAR-T cells targets and binds to CTLA4 expressed on T-cells, and inhibits the CTLA4-mediated downregulation of T-cell activation. Both antibodies enhance T-cell activation, improve immunosuppression in the tumor microenvironment (TME) and improve the T-cell mediated immune response against and toxicity in EGFR-expressing tumor cells. Both PD-1 and CTLA-4 negatively regulate T-cell activation and proliferation, and play a key role in immunosuppression within the TME. EGFR, a receptor tyrosine kinase that is overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation.","A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.","A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,true,true,true,true,true,false,false,true,true,true,false,true,true,true,true,true,true,true,true,false,false,true,false,true,true,true,true,true,true,true,true,true,true,true,false,false,true,true,false,true,true,true,true,true,true,true,true,false,false,true,true,true,true,false,false,true,true,true,true,false,false,true,true,false,true,true,true,true,true,true,true,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,false,false,true,true,false,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA"],["C126799","C121540","C116870","C103194","C106250","C68814","C106432","C2654","NA","NA","C124058","C132992","C136465","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","C142168","C121775","C49085","NA","NA","C121625","C124229","C124229","C124229","C124229","NA","C132192","NA","NA","C129714","C71014","NA","NA","C126113","NA","NA","NA","C128138","C126660","C66983","C125659","C97039","C141421","C137820","C142978","C156741","C150463","C150463","C157578","C174140","C165270","C160605","C160605","C142822","C172194","C172194","C148535","C155967","C156490","C176746","C173891","C142077","C176868","C153149","C160714","C125718","C159530","C159530","C173540","C148155","C162636","C176872","C171841","C173539","C171937","C161597","C172819","C174515","C174419","C148159","C158505","C150756","C150403","C156726","C163992","C157127","C155931","C124946","C179552","C188211","C157242","C175555","C125903","C191689","C178280","C156893","C191738","C187159","C181748","C170900","C179629","C150393","C186440","C187338","C158532","C175374","C128037","C160716","C169063","C173435","C128057","C187653","C148042","C180410","C180682","C172820","C178345","C174171","C179331","C182009","C178320","C174520","C129594","C129594","C129594","C176841","C185282","C142865","C176874","C179266","C184307","C174192","C175603","C176873","C156177","C187128","C162871","C185390","C178405","C168600","C168600","C131537","C159538","C173592","C188066","C156791","C174037","C187179","C150560","C190780","C190780","C188361","C180830","C166139","C179276","C186372","C175970","C180687","C123267","C168603","C179260","C174485","C186492","C113332","C185858","C156692","C185391","C185395","C173630","C179329","C172108","C181753","C190185","C173547","C78852","C183161","C173706","C175468","C142374","C176029","C162505","C159764","C124783","C185425","C170909","C179665","C179278","C179278","C190630","C190630","C178569","C187102","C187105","C131907","C191777","C150734","C150734","C179258","C179258","C162625","C173422","C176983","C185426","C185426","C162774","C162774","C178282","C178449","C178449","C190124","C160772","C184375","C184375","C157494","C157494","C159978","C157058","C157058","C182073","C185163","C171938","C171938","C180907","C180907","C187980","C187980","C187101","C187101","C148216","C184379","C184379","C185600","C185600","C181022","C181022","C179633","C181016","C181016","C179637","C185605","C185605","C185285","C185285","C188244","C188244","C185160","C185160","C186549","C180675","C180675","C181773","C178409","C180866","C180866","C176870","C189813","C181027","C186661","C185119","C175945","C172196","C172196","C132251","C150695","C150695","C150682","C150682"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,false,true,true,true,true,true,true,true,true,false,true,true,true,false,true,false,true,true,true,true,true,true,true,true,false,true,true,true,false,true,true,true,true,true,false,false,true,true,true,false,false,true,true,true,true,true,true,true,false,false,true,false,false,true,true,true,false,true,true,true,true,true,false,false,false,true,true,false,false,true,false,false,false,false,false,false,false,false,false,false,true,true,false,false,true,true,true,true,false,false,true,true,false,true,true,true,true,false,false,false,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,false,false,false,true,true,true,true,true,true,true,true,true,true,true,false,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,true,true,false,true,true,true,true,false,true,true,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["Programmed Death Receptor-1 Blocking Antibody [EPC]",null,"Programmed Death Ligand-1 Blocker [EPC]","Programmed Death Ligand-1 Blocker [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","CTLA-4-directed Blocking Antibody [EPC]",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[5133,5133,29126,29126,29126,5133,5133,1493,5133,5133,5133,5133,5133,201633,1493,5133,29126,201633,5133,5133,201633,29126,1493,5133,5133,5133,1493,201633,5133,5133,29126,7040,7042,7043,5133,29126,1493,5133,29126,5133,3902,5133,1493,201633,201633,5133,29126,7852,972,135,5133,201633,84868,3902,29126,1493,5133,5133,null,29126,29126,5133,null,29126,3604,29126,79679,387597,null,null,3902,961,5133,null,961,1493,3902,1493,5133,5133,201633,4680,null,null,5133,null,1493,2064,5133,1493,961,3902,5133,29126,3902,29126,5133,null,null,84868,961,null,29126,5133,29126,1493,29126,29126,29126,135,null,null,29126,29126,3135,5133,null,null,1493,29126,961,84868,null,null,5133,5133,null,961,5133,5133,29126,29126,80380,64115,null,3902,5133,5133,29126,201633,961,961,1493,3902,3903,5133,5133,5133,961,5133,29126,29126,29126,201633,79037,201633,201633,84868,3902,5133,961,961,1493,1493,1493,1493,1493,29851,3902,3902,null,null,5133,5133,29126,201633,201633,201633,84868,84868,135,696,1493,29126,201633,null,135,135,10225,1493,1493,7293,5133,5133,29126,961,140885,961,140885,135,135,79037,201633,7133,29126,3902,3902,5133,84868,1493,29126,29126,7040,1493,5133,50943,1493,5133,29126,29126,29126,7040,1493,7293,29126,29126,84868,3135,5133,29126,5133,5133,201633,84868,5133,29126,7293,1493,29126,961,2064,5133,29126,3902,5133,84868,5133,29126,29126,961,29126,3902,29126,201633,29126,201633,null,29126,51208,null,null,29126,961,null,5133,5133,5133,29126,5133,1493,5133,5133,1493,5133,1493,5133],["ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000120217","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000105329","ENSG00000092969","ENSG00000119699","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000089692","ENSG00000188389","ENSG00000163599","ENSG00000181847","ENSG00000181847","ENSG00000188389","ENSG00000120217","ENSG00000121966","ENSG00000019582","ENSG00000128271","ENSG00000188389","ENSG00000181847","ENSG00000135077","ENSG00000089692","ENSG00000120217","ENSG00000163599","ENSG00000188389","ENSG00000188389",null,"ENSG00000120217","ENSG00000120217","ENSG00000188389",null,"ENSG00000120217","ENSG00000049249","ENSG00000120217","ENSG00000134258","ENSG00000143195",null,null,"ENSG00000089692","ENSG00000196776","ENSG00000188389",null,"ENSG00000196776","ENSG00000163599","ENSG00000089692","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000086548",null,null,"ENSG00000188389",null,"ENSG00000163599","ENSG00000141736","ENSG00000188389","ENSG00000163599","ENSG00000196776","ENSG00000089692","ENSG00000188389","ENSG00000120217","ENSG00000089692","ENSG00000120217","ENSG00000188389",null,null,"ENSG00000135077","ENSG00000196776",null,"ENSG00000120217","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000128271",null,null,"ENSG00000120217","ENSG00000120217","ENSG00000204632","ENSG00000188389",null,null,"ENSG00000163599","ENSG00000120217","ENSG00000196776","ENSG00000135077",null,null,"ENSG00000188389","ENSG00000188389",null,"ENSG00000196776","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000197646","ENSG00000107738",null,"ENSG00000089692","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000181847","ENSG00000196776","ENSG00000196776","ENSG00000163599","ENSG00000089692","ENSG00000167613","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000196776","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000181847","ENSG00000213413","ENSG00000181847","ENSG00000181847","ENSG00000135077","ENSG00000089692","ENSG00000188389","ENSG00000196776","ENSG00000196776","ENSG00000163599","ENSG00000163599","ENSG00000163599","ENSG00000163599","ENSG00000163599","ENSG00000163600","ENSG00000089692","ENSG00000089692",null,null,"ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000181847","ENSG00000181847","ENSG00000181847","ENSG00000135077","ENSG00000135077","ENSG00000128271","ENSG00000124557","ENSG00000163599","ENSG00000120217","ENSG00000181847",null,"ENSG00000128271","ENSG00000128271","ENSG00000153283","ENSG00000163599","ENSG00000163599","ENSG00000186827","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000196776","ENSG00000198053","ENSG00000196776","ENSG00000198053","ENSG00000128271","ENSG00000128271","ENSG00000213413","ENSG00000181847","ENSG00000028137","ENSG00000120217","ENSG00000089692","ENSG00000089692","ENSG00000188389","ENSG00000135077","ENSG00000163599","ENSG00000120217","ENSG00000120217","ENSG00000105329","ENSG00000163599","ENSG00000188389","ENSG00000049768","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000105329","ENSG00000163599","ENSG00000186827","ENSG00000120217","ENSG00000120217","ENSG00000135077","ENSG00000204632","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000135077","ENSG00000188389","ENSG00000120217","ENSG00000186827","ENSG00000163599","ENSG00000120217","ENSG00000196776","ENSG00000141736","ENSG00000188389","ENSG00000120217","ENSG00000089692","ENSG00000188389","ENSG00000135077","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000196776","ENSG00000120217","ENSG00000089692","ENSG00000120217","ENSG00000181847","ENSG00000120217","ENSG00000181847",null,"ENSG00000120217","ENSG00000066405",null,null,"ENSG00000120217","ENSG00000196776",null,"ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000163599","ENSG00000188389"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","protein_family","protein_family","protein_family","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,"single_protein","single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,null,"single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein",null,"single_protein","single_protein",null,null,"single_protein","single_protein",null,"single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein"],[2021,2018,2017,2017,2016,2015,2014,2011,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,4,4,4,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["angiosarcoma, breast cancer, cancer, cervical cancer, cervical carcinoma, endometrial cancer, head and neck malignant neoplasia, liver cancer, melanoma, mesothelioma, multiple myeloma, non-small cell lung carcinoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, rectum cancer, sarcoma, small cell lung carcinoma","angiosarcoma, basal cell carcinoma, breast cancer, cancer, cervical cancer, diffuse intrinsic pontine glioma, fallopian tube cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hodgkins lymphoma, lung cancer, lymphoma, melanoma, multiple myeloma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, pancreatic carcinoma, prostate cancer, skin cancer, squamous cell carcinoma","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, breast cancer, breast carcinoma, breast neoplasm, cancer, chordoma, chronic myelogenous leukemia, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, fallopian tube cancer, follicular lymphoma, gastric adenocarcinoma, gestational trophoblastic neoplasm, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, leiomyosarcoma, lymphoma, malignant colon neoplasm, malignant glioma, melanoma, meningioma, mesothelioma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, prostate cancer, rectum cancer, renal carcinoma, skin cancer, small cell lung carcinoma, squamous cell carcinoma, thymic carcinoma, thymoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, anal carcinoma, angiosarcoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, dysgerminoma, endometrial neoplasm, esophageal cancer, esophageal squamous cell carcinoma, fallopian tube carcinoma, follicular lymphoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, large cell lung carcinoma, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid neoplasm, lymphoma, malignant pleural mesothelioma, melanoma, mesothelioma, mouth neoplasm, multiple myeloma, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary thyroid carcinoma, plasmacytoma, polycythemia vera, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, rectum cancer, sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, alveolar soft part sarcoma, anus cancer, biliary tract cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cervical carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal carcinoma, cutaneous melanoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, follicular lymphoma, gastric adenocarcinoma, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, lung cancer, lymphoma, malignant glioma, malignant pleural mesothelioma, melanoma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, rectum cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, thyroid carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adrenal cortex carcinoma, anaplastic large cell lymphoma, angiosarcoma, basal cell carcinoma, biliary tract cancer, biliary tract neoplasm, brain cancer, brain neoplasm, breast cancer, breast carcinoma, cancer, central nervous system cancer, cervical cancer, cervical carcinoma, childhood acute lymphoblastic leukemia, cholangiocarcinoma, chordoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, dedifferentiated liposarcoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, endometrial carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lymphoid neoplasm, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, mantle cell lymphoma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oligodendroglioma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, t-cell non-hodgkin lymphoma, thyroid cancer, thyroid carcinoma, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, unspecified peripheral t-cell lymphoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adrenal cortex carcinoma, adult lymphoma, alveolar soft part sarcoma, anal carcinoma, angiosarcoma, anus cancer, asymptomatic myeloma, b-cell acute lymphoblastic leukemia, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast carcinoma in situ, breast ductal carcinoma in situ, breast neoplasm, cancer, carcinoma of liver and intrahepatic biliary tract, cervical adenocarcinoma, cervical cancer, cervical carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, endometrial cancer, endometrial carcinoma, endometrial neoplasm, epithelioid sarcoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, gliosarcoma, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, laryngeal squamous cell carcinoma, leukemia, lung adenocarcinoma, lung cancer, lymphoid leukemia, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant glioma, malignant peripheral nerve sheath tumor, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medullary thyroid gland carcinoma, melanoma, meningeal neoplasm, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, mouth neoplasm, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharynx cancer, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, parotid gland cancer, pediatric lymphoma, penile carcinoma, peritoneal neoplasm, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland carcinoma, sarcoma, sezary's disease, skin basal cell carcinoma, skin cancer, skin carcinoma, skin neoplasm, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thymic carcinoma, thymoma, thyroid cancer, thyroid carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, vulvar carcinoma, waldenstrom macroglobulinemia","acute lymphoblastic leukemia, acute myeloid leukemia, basal cell carcinoma, biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cervical carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, cutaneous melanoma, dedifferentiated liposarcoma, diffuse large b-cell lymphoma, endometrial carcinoma, esophageal cancer, esophageal carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, grade iii meningioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, liver cancer, lung adenocarcinoma, lung cancer, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, prostate carcinoma, rectum cancer, salivary gland cancer, sarcoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell lung carcinoma, synovial sarcoma, thyroid cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","bladder tumor, cancer, multiple myeloma, prostate adenocarcinoma, urothelial carcinoma","breast cancer, cancer, colorectal carcinoma, hepatocellular carcinoma, hodgkins lymphoma, lung cancer, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic carcinoma, squamous cell lung carcinoma","non-small cell lung carcinoma, prostate adenocarcinoma, urinary bladder cancer","angioimmunoblastic t-cell lymphoma, biliary tract cancer, breast cancer, cancer, cervical adenocarcinoma, cervical cancer, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, lung cancer, lung neoplasm, lymphoma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, unspecified peripheral t-cell lymphoma","angiosarcoma, bladder tumor, cancer, cervical cancer, diffuse intrinsic pontine glioma, soft tissue sarcoma","cancer, cervical cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, colorectal carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, small cell lung carcinoma","breast cancer, cancer, cervical cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, gastric adenocarcinoma, hepatocellular carcinoma, hodgkins lymphoma, lymphoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, cervical cancer, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma","biliary tract cancer, biliary tract neoplasm, breast cancer, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colonic neoplasm, colorectal carcinoma, esophageal cancer, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liposarcoma, lymphoma, malignant pleural mesothelioma, melanoma, metastatic melanoma, mouth neoplasm, nasopharyngeal neoplasm, neoplasm of hypopharynx, non-small cell lung carcinoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, thyroid cancer, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urothelial carcinoma","acute myeloid leukemia, adrenal cortex carcinoma, biliary tract cancer, bladder tumor, breast cancer, cancer, cervical cancer, cervical carcinoma, cholangiocarcinoma, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, intrahepatic cholangiocarcinoma, liver cancer, lung cancer, lung carcinoma, lung neoplasm, lymphoma, malignant colon neoplasm, melanoma, mouth neoplasm, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, thyroid cancer, triple-negative breast cancer","cancer, glioblastoma multiforme, non-small cell lung carcinoma","cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, lymphoma, non-small cell lung carcinoma, thymic carcinoma, triple-negative breast cancer","cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, lymphoma, non-small cell lung carcinoma, thymic carcinoma, triple-negative breast cancer","cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, thyroid cancer, urinary bladder cancer","breast cancer, cancer, endometrial cancer, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, sarcoma, soft tissue sarcoma, squamous cell carcinoma, triple-negative breast cancer, urothelial carcinoma","biliary tract cancer, breast cancer, cancer, cervical cancer, classic hodgkin lymphoma, diffuse large b-cell lymphoma, esophageal cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck malignant neoplasia, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, leukemia, lung cancer, lymphoma, melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, small cell lung carcinoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, dysgerminoma, esophageal cancer, fallopian tube cancer, fallopian tube carcinoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, lung cancer, lymphoid neoplasm, lymphoma, melanoma, mesothelioma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary thyroid carcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, sarcoma, seminoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell lung carcinoma, thyroid cancer, urinary bladder cancer, urothelial carcinoma","cancer, melanoma, non-small cell lung carcinoma, prostate cancer","cancer, cervical cancer, classic hodgkin lymphoma, glioblastoma multiforme, non-small cell lung carcinoma, pancreatic carcinoma, prostate adenocarcinoma","breast cancer, cancer, cutaneous melanoma, esophageal squamous cell carcinoma, gastric cancer, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung cancer, lymphoma, melanoma, multiple myeloma, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, triple-negative breast cancer","breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, esophageal carcinoma, gastric cancer, head and neck squamous cell carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, metastatic prostate cancer, non-small cell lung carcinoma, pancreatic carcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, soft tissue sarcoma, thymoma","breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, esophageal carcinoma, gastric cancer, head and neck squamous cell carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, metastatic prostate cancer, non-small cell lung carcinoma, pancreatic carcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, soft tissue sarcoma, thymoma","breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, esophageal carcinoma, gastric cancer, head and neck squamous cell carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, metastatic prostate cancer, non-small cell lung carcinoma, pancreatic carcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, soft tissue sarcoma, thymoma","breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, esophageal carcinoma, gastric cancer, head and neck squamous cell carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, metastatic prostate cancer, non-small cell lung carcinoma, pancreatic carcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, soft tissue sarcoma, thymoma","alveolar soft part sarcoma, cancer, cervical cancer, neoplasm of mature b-cells, non-small cell lung carcinoma, unspecified peripheral t-cell lymphoma","breast cancer, lymphoma, metastatic melanoma","cancer, cervical cancer, hepatocellular carcinoma, lung cancer, melanoma, nasopharyngeal neoplasm, non-small cell lung carcinoma","cancer, cervical cancer, hepatocellular carcinoma, lung cancer, melanoma, nasopharyngeal neoplasm, non-small cell lung carcinoma","biliary tract neoplasm, breast cancer, cancer, hepatocellular carcinoma","diffuse large b-cell lymphoma, hepatocellular carcinoma, lymphoma, melanoma, multiple myeloma, pancreatic carcinoma, prostate adenocarcinoma","breast cancer, endometrial carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma","breast cancer, endometrial carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma","angiosarcoma, bladder tumor, cancer, cervical cancer, diffuse intrinsic pontine glioma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, soft tissue sarcoma","cancer, lung cancer","cancer","breast cancer, cancer, colorectal carcinoma, head and neck malignant neoplasia, ovarian cancer, small cell lung carcinoma","breast cancer, cancer, cutaneous melanoma, pancreatic carcinoma","clear cell renal carcinoma, melanoma, waldenstrom macroglobulinemia","chronic lymphocytic leukemia, lymphoma, multiple myeloma, plasmacytoma","multiple myeloma, non-small cell lung carcinoma","cancer, colorectal carcinoma","cancer, glioblastoma multiforme","breast cancer, cancer, cutaneous melanoma, pancreatic carcinoma","cancer","cancer","cancer","cancer","cancer","","cancer","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","","","cancer","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","","cancer","cancer","cancer","cancer","","","cancer","cancer","cancer","cancer","","","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","","cancer","cancer","","","cancer","cancer","","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer","cancer"],["1|2|3|4","1|2|3|4","0|1|2|3|4","1|2|3|4","1|2|3|4","1|2|3|4","0|1|2|3|4","1|2|3|4","1|2|3","1|2|3","1|2|3","0|1|2|3","1|2|3","1|2|3","1|2","1|2|3","1|2|3","1|2|3","1|2|3","1|2|3","0|1|3","1|2|3","1|2|3","1|2|3","1|2|3","1|2|3","0|1|2|3","1|3","0|1|2|3","1|2|3","1|2|3","1|2|3","1|2|3","1|2|3","1|2","1|2","1|2","1|2","1|2","1|2","1|2","1|2","1|2","1","1","1","1","1","1","1","1","1","1","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>immune_checkpoint_inhibitor<\/th>\n      <th>topoisomerase_inhibitor<\/th>\n      <th>iap_inhibitor<\/th>\n      <th>tubulin_inhibitor<\/th>\n      <th>kinase_inhibitor<\/th>\n      <th>hdac_inhibitor<\/th>\n      <th>parp_inhibitor<\/th>\n      <th>bet_inhibitor<\/th>\n      <th>monoclonal_antibody<\/th>\n      <th>antimetabolite<\/th>\n      <th>angiogenesis_inhibitor<\/th>\n      <th>alkylating_agent<\/th>\n      <th>anthracycline<\/th>\n      <th>platinum_compound<\/th>\n      <th>proteasome_inhibitor<\/th>\n      <th>hormone_therapy<\/th>\n      <th>hedgehog_antagonist<\/th>\n      <th>fda_epc_category<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indicaton_max_phase<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,33,36,37]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
</div>
<div class="section level3">
<h3 id="get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-colonrectum-list-per-drug-target-entry">Get immune checkpoint inhibitors indicated for tumor subtypes within
â€œColon/Rectumâ€, list per drug-target entry<a class="anchor" aria-label="anchor" href="#get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-colonrectum-list-per-drug-target-entry"></a>
</h3>
<div class="sourceCode" id="cb5"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span></span>
<span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
<span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
<span>  is_immune_checkpoint_inhibitor <span class="op">=</span> <span class="cn">T</span>,</span>
<span>  output_resolution <span class="op">=</span> <span class="st">"drug2target"</span>, </span>
<span>  drug_indication_main <span class="op">=</span> <span class="st">"Colon/Rectum"</span><span class="op">)</span></span>
<span></span>
<span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> </span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>    <span class="op">-</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"drug_alias"</span>,</span>
<span>       <span class="st">"disease_main_group"</span>,</span>
<span>       <span class="st">"drug_clinical_id"</span><span class="op">)</span><span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/mutate.html" class="external-link">mutate</a></span><span class="op">(</span></span>
<span>    disease_indication <span class="op">=</span> <span class="fu">stringr</span><span class="fu">::</span><span class="fu"><a href="https://stringr.tidyverse.org/reference/str_replace.html" class="external-link">str_replace_all</a></span><span class="op">(</span></span>
<span>      <span class="va">disease_indication</span>, <span class="st">"\\|"</span>,<span class="st">", "</span><span class="op">)</span></span>
<span>    <span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drug_id</span>,</span>
<span>    <span class="va">drug_name</span>,</span>
<span>    <span class="va">drug_type</span>,</span>
<span>    <span class="va">target_symbol</span>,</span>
<span>    <span class="va">target_genename</span>,</span>
<span>    <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://tidyselect.r-lib.org/reference/everything.html" class="external-link">everything</a></span><span class="op">(</span><span class="op">)</span></span>
<span>  <span class="op">)</span></span>
<span></span>
<span><span class="va">dt_drugtable3</span> <span class="op">&lt;-</span> <span class="fu">DT</span><span class="fu">::</span><span class="fu"><a href="https://rdrr.io/pkg/DT/man/datatable.html" class="external-link">datatable</a></span><span class="op">(</span></span>
<span>  <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>  escape <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  extensions <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"Buttons"</span>, <span class="st">"Responsive"</span><span class="op">)</span>, </span>
<span>  width <span class="op">=</span> <span class="st">"100%"</span>,</span>
<span>  options <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span></span>
<span>    buttons <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"csv"</span>, <span class="st">"excel"</span><span class="op">)</span>, </span>
<span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
<span><span class="op">)</span></span></code></pre></div>
<p><br></p>
<div id="htmlwidget-3a736db44a7ad54df845" style="width:100%;height:auto;" class="datatables html-widget "></div>
<script type="application/json" data-for="htmlwidget-3a736db44a7ad54df845">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19"],[3003,1719,3048,1315,5355,5794,4299,5805,6677,6195,7200,2161,7253,1945,1945,1945,1945,2083,1053],["Dostarlimab","Avelumab","Durvalumab","Atezolizumab","Nivolumab","Pembrolizumab","Ipilimumab","Penpulimab","Sintilimab","Quavonlimab","Toripalimab","Camrelizumab","Tremelimumab","Bintrafusp Alfa","Bintrafusp Alfa","Bintrafusp Alfa","Bintrafusp Alfa","Budigalimab","Anti-PD-1 Fusion Protein AMP-224"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Protein","Protein","Protein","Protein","Antibody","Antibody"],["PDCD1","CD274","CD274","CD274","PDCD1","PDCD1","CTLA4","PDCD1","PDCD1","CTLA4","PDCD1","PDCD1","CTLA4","CD274","TGFB1","TGFB2","TGFB3","PDCD1","PDCD1"],["programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","transforming growth factor beta 1","transforming growth factor beta 2","transforming growth factor beta 3","programmed cell death 1","programmed cell death 1"],["CHEMBL4298124","CHEMBL3833373","CHEMBL3301587","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL1789844","CHEMBL4297571","CHEMBL4297829","CHEMBL4650419","CHEMBL4297843","CHEMBL4297715","CHEMBL2108658","CHEMBL4298024","CHEMBL4298024","CHEMBL4298024","CHEMBL4298024","CHEMBL4297858","CHEMBL4297570"],["ANTAGONIST","OTHER","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","ANTAGONIST","INHIBITOR","BINDING AGENT","BINDING AGENT","BINDING AGENT","BINDING AGENT","INHIBITOR","INHIBITOR"],["A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","NA","A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[true,false,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C126799","C116870","C103194","C106250","C68814","C106432","C2654","NA","C132992","NA","NA","NA","C49085","C124229","C124229","C124229","C124229","NA","C97039"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["Programmed Death Receptor-1 Blocking Antibody [EPC]","Programmed Death Ligand-1 Blocker [EPC]","Programmed Death Ligand-1 Blocker [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","Programmed Death Receptor-1 Blocking Antibody [EPC]","CTLA-4-directed Blocking Antibody [EPC]",null,null,null,null,null,null,null,null,null,null,null,null],[5133,29126,29126,29126,5133,5133,1493,5133,5133,1493,5133,5133,1493,29126,7040,7042,7043,5133,5133],["ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000120217","ENSG00000105329","ENSG00000092969","ENSG00000119699","ENSG00000188389","ENSG00000188389"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","protein_family","protein_family","protein_family","single_protein","single_protein"],[2021,2017,2017,2016,2015,2014,2011,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,4,4,3,3,3,3,3,3,3,3,3,3,1,1],["rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, rectum cancer","anus cancer, colorectal carcinoma, rectum cancer","colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anal carcinoma, anus cancer, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, malignant colon neoplasm, rectum cancer","colorectal carcinoma","colorectal adenocarcinoma, colorectal carcinoma, rectum cancer","colorectal carcinoma","colonic neoplasm, colorectal carcinoma","colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm","colorectal adenocarcinoma","colorectal adenocarcinoma","colorectal adenocarcinoma","colorectal adenocarcinoma","colorectal carcinoma","colorectal carcinoma"],["2","2|3","2","2|3","2","2|3","2","2","1|2","2","1|2","2","2","2","2","2","2","1","1"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>immune_checkpoint_inhibitor<\/th>\n      <th>topoisomerase_inhibitor<\/th>\n      <th>iap_inhibitor<\/th>\n      <th>tubulin_inhibitor<\/th>\n      <th>kinase_inhibitor<\/th>\n      <th>hdac_inhibitor<\/th>\n      <th>parp_inhibitor<\/th>\n      <th>bet_inhibitor<\/th>\n      <th>monoclonal_antibody<\/th>\n      <th>antimetabolite<\/th>\n      <th>angiogenesis_inhibitor<\/th>\n      <th>alkylating_agent<\/th>\n      <th>anthracycline<\/th>\n      <th>platinum_compound<\/th>\n      <th>proteasome_inhibitor<\/th>\n      <th>hormone_therapy<\/th>\n      <th>hedgehog_antagonist<\/th>\n      <th>fda_epc_category<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indicaton_max_phase<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,33,36,37]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
</div>
<div class="section level3">
<h3 id="get-antimetabolite-drugs">Get antimetabolite drugs<a class="anchor" aria-label="anchor" href="#get-antimetabolite-drugs"></a>
</h3>
<div class="sourceCode" id="cb6"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span></span>
<span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
<span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
<span>  is_antimetabolite <span class="op">=</span> <span class="cn">T</span>,</span>
<span>  output_resolution <span class="op">=</span> <span class="st">"drug"</span><span class="op">)</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Reading from cache_dir = '/tmp/RtmpvilFeM', argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Object 'drug_map_name' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Retrieved n = 7653 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Reading from cache_dir = '/tmp/RtmpvilFeM', argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Object 'drug_map_alias' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Retrieved n = 187616 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Reading from cache_dir = '/tmp/RtmpvilFeM', argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Object 'drug_map_basic' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Retrieved n = 7654 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Reading from cache_dir = '/tmp/RtmpvilFeM', argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Object 'drug_map_target' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Retrieved n = 11822 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Reading from cache_dir = '/tmp/RtmpvilFeM', argument force_download = F</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Object 'drug_map_indication' sucessfully loaded</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:36] Retrieved n = 28407 records</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:37] Record set satisfying user-defined criteria: n = 4572</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:37] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
<span><span class="co">#&gt; INFO  [2023-01-12 13:25:37] Final record set: n = 73 records</span></span>
<span></span>
<span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> </span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/select.html" class="external-link">select</a></span><span class="op">(</span></span>
<span>    <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>    <span class="op">-</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"drug_alias"</span>,</span>
<span>       <span class="st">"disease_main_group"</span>,</span>
<span>       <span class="st">"drug_clinical_id"</span><span class="op">)</span><span class="op">)</span> <span class="op">|&gt;</span></span>
<span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/mutate.html" class="external-link">mutate</a></span><span class="op">(</span></span>
<span>    disease_indication <span class="op">=</span> <span class="fu">stringr</span><span class="fu">::</span><span class="fu"><a href="https://stringr.tidyverse.org/reference/str_replace.html" class="external-link">str_replace_all</a></span><span class="op">(</span></span>
<span>      <span class="va">disease_indication</span>, <span class="st">"\\|"</span>,<span class="st">", "</span><span class="op">)</span></span>
<span>    <span class="op">)</span></span>
<span></span>
<span><span class="va">dt_drugtable4</span> <span class="op">&lt;-</span> <span class="fu">DT</span><span class="fu">::</span><span class="fu"><a href="https://rdrr.io/pkg/DT/man/datatable.html" class="external-link">datatable</a></span><span class="op">(</span></span>
<span>  <span class="va">drugs</span><span class="op">$</span><span class="va">records</span>,</span>
<span>  escape <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  extensions <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"Buttons"</span>, <span class="st">"Responsive"</span><span class="op">)</span>, </span>
<span>  width <span class="op">=</span> <span class="st">"100%"</span>,</span>
<span>  options <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span></span>
<span>    buttons <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"csv"</span>, <span class="st">"excel"</span><span class="op">)</span>, </span>
<span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
<span><span class="op">)</span></span></code></pre></div>
<p><br></p>
<div id="htmlwidget-54ad64a83529ab658622" style="width:100%;height:auto;" class="datatables html-widget "></div>
<script type="application/json" data-for="htmlwidget-54ad64a83529ab658622">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73"],[2373,2802,1741,2557,2182,3737,6421,3538,2729,4066,7078,3564,4870,4842,6980,1275,3864,2048,4629,7164,7047,1305,7039,111,2634,6906,6482,6496,3738,3640,3741,2259,7097,2541,4451,5266,1855,7412,3191,247,7076,2874,3553,6161,7080,22,3192,33,3563,5523,6769,59,212,1222,2635,44,4143,5527,1221,2803,3052,4844,3229,3740,3372,2731,7273,3743,2183,4582,2374,4873,6981],["Cedazuridine","Decitabine","Azacitidine","Clofarabine","Capecitabine","Gemcitabine","Ribavirin","Floxuridine","Cytarabine","Hydroxyurea","Thioguanine","Fluorouracil","Methotrexate","Mercaptopurine","Tegafur","Arfolitixorin","Guadecitabine","Brivudine","Lometrexol","Tocladesine","Tezacitabine","Aspacytarabine","Tetrahydrouridine","Acadesine","Cordycepin","Talotrexin","Roducitabine","Ropidoxuridine","Gemcitabine Elaidate","Fosifloxuridine Nafalbenamide","Gemcitabine Prodrug LY2334737","Carmofur","Tiazofurin","Cladribine","Lamivudine","Nelarabine","Bendamustine","Valganciclovir","Emitefur","Alanosine","Thiarabine","Dezaguanine","Fludarabine","Pteropterin","Thioinosine","2-Fluoroadenine","Emofolin Sodium","3-AP/Fludarabine","Fluoropyrimidine","Oral Azacitidine","Sparfosate Sodium","9H-Purine-6Thio-98D","Aerosol Gemcitabine","Antimetabolite FF-10502","Cordycepin Triphosphate","5-Fluoro-2-Deoxycytidine","IGF-methotrexate Conjugate","Oral Fludarabine Phosphate","Antimetabolite Chemotherapy","Decitabine and Cedazuridine","dUTPase/DPD Inhibitor TAS-114","Mercaptopurine Oral Suspension","Eniluracil/5-FU Combination Tablet","Gemcitabine Hydrochloride Emulsion","Etidronate-Cytarabine Conjugate MBC-11","Cytarabine Monophosphate Prodrug MB07133","Trifluridine and Tipiracil Hydrochloride","Gemcitabine-Releasing Intravesical System","Capecitabine Rapidly Disintegrating Tablet","Liposome-encapsulated Daunorubicin-Cytarabine","Cedazuridine/Azacitidine Combination Agent ASTX030","Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Small molecule",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["CHEMBL3237547","CHEMBL1201129","CHEMBL1489","CHEMBL1750","CHEMBL1773","CHEMBL888","CHEMBL1643","CHEMBL917","CHEMBL803","CHEMBL467","CHEMBL727","CHEMBL185","CHEMBL34259","CHEMBL1425","CHEMBL20883","CHEMBL1234270","CHEMBL3544916","CHEMBL31634","CHEMBL34412","CHEMBL2107085","CHEMBL2105467","CHEMBL4297599","CHEMBL1236475","CHEMBL1551724","CHEMBL305686","CHEMBL590985","CHEMBL2064455","CHEMBL2103821","CHEMBL3039516","CHEMBL2181367","CHEMBL577711","CHEMBL460499","CHEMBL108358","CHEMBL1619","CHEMBL141","CHEMBL1201112","CHEMBL487253","CHEMBL1201314",null,"CHEMBL452715","CHEMBL1631221","CHEMBL31882","CHEMBL1568",null,"CHEMBL448290",null,null,null,null,null,null,null,null,null,"CHEMBL480329",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","NA","NA","INHIBITOR","INHIBITOR","NA","NA","INHIBITOR","NA","INHIBITOR","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","INHIBITOR","NA","NA","NA","NA","NA","INHIBITOR","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA"],["An orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.","A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.","A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.","A uridine derivative and nucleoside analog with pro-apoptotic and chemosensitizing properties. In vitro, bromovinyl-deoxyuridine (BVDU) has been shown to downregulate the multifunctional DNA repair enzyme APEX nuclease 1, resulting in the inhibition of DNA repair and the induction of apoptosis. In addition, this agent may inhibit the expression of STAT3 (signal transducer and activator of transcription 3), which may result in the downregulation of vascular endothelial growth factor (VEGF). BVDU has also been found to inhibit the upregulation of chemoresistance genes (Mdr1 and DHFR) during chemotherapy. Overall, the gene expression changes associated with BVDU treatment result in the decrease or prevention of chemoresistance. In addition, this agent has been shown to enhance the cytolytic activity of NK-92 natural killer cells towards a pancreatic cancer cell line in vitro.","A folate analog antimetabolite with antineoplastic activity. As the 6R diastereomer of 5,10-dideazatetrahydrofolate, lometrexol inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate. (NCI04)","An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a purine analogue and competes with ATP in transcription. In addition, generation of 8-chloro-ATP depletes endogenous ATP pool that is essential for many biological reactions in intracellular energy transfer. As a result, this agent causes RNA synthesis inhibition, blocks cellular proliferation, and induces apoptosis.","A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types.","A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.","A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","A 5-aminoimidazole-4-carboxamide (AICA) riboside, a ribnucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis. Acadesine-induced apoptosis also appears to require cytochrome c release from mitochondria and caspase activation and is p53-independent. However, the exact mechanism of acadesine-induced apoptosis is unknown. T cells are significantly less susceptible than B cells to acadesine-induced apoptosis. AMPK regulates several cellular systems including the cellular uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria.","A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","An antimetabolite analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.","An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.","An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","A lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase.","A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.","An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.","An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI)","A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.","An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.","A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","A purine nucleoside analogue with antineoplastic and antiviral activities.  By replacing guanine, dezaguanine incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI)","A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","A crystalline conjugate of folic acid, having general properties of a polypeptide. Pteropterin differs from folic acid in that it consists of three molecules of glutamic acid instead of one. Pteropterin can potentially be used as an antimetabolite in the treatment of cancer.","A sulfhydryl analog of inosine and an antimetabolite with potential antineoplastic and immunosuppressive properties. Thioinosine interferes with de novo purine synthesis and perturbs the pool of nucleotides necessary for DNA replication. As a result, this agent inhibits DNA synthesis, blocks cellular proliferation and induces apoptosis.","A fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies.","The sodium salt of a synthetic antimetabolite analogue of folate with antineoplastic activity.  Emfolin sodium competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, depletion of nucleotide pools, and inhibition of DNA, RNA and protein synthesis. (NCI04)","A combination of the thiosemicarbazone 3-aminopyridine-2-carboxaldehyde (3-AP) and the nucleoside analogue fludarabine with antineoplastic activity. The agents in 3-AP/fludarabine, act synergistically to inhibit the enzyme ribonucleotide reductase.. Composed of two subunits, this enzyme catalyzes the rate-limiting step in the conversion of ribonucleotides to deoxyribonucleotides. The 3-AP binds to and inactivates one subunit while fludarabine binds to and inactivates the other.  Fludarabine also inhibits DNA polymerase alpha and DNA primase. At low concentrations, this agent arrests tumor cells in the S-phase of the cell cycle; at higher concentrations, in the G0/G1 phase of the cell cycle. (NCI04)","Any fluoropyrimidine-based agent with potential antineoplastic activity. As an antimetabolite, a fluoropyrimidine interferes with pyrimidine utilization and incorporation into DNA and RNA.","An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.","The disodium salt form of N-phosphonacetyl-L-aspartate (PALA), a pyrimidine antimetabolite with antineoplastic activity.  PALA inhibits pyrimidine biosynthesis and increases the extent to which fluorouracil is incorporated into RNA. (NCI04)","An antimetabolite analogue of purine with antineoplastic and immuno-suppressant properties.  9H-Purine-6Thio-98D substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. In vivo, this agent, also known as 6MP-arabinoside, may occur as a metabolite of the antineoplastic agent mercaptopurine. (NCI04)","An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.","An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.","The triphosphate salt of cordycepin, a purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK), and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.","An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported into malignant cells and metabolized by deoxycytidine kinase to its active form, 2-fluoro-ara-ATP; 2-fluoro-ara-ATP competes directly with deoxyadenosine triphosphate (dATP) and inhibits alpha DNA polymerase, RNA reductase, and DNA primase, which may result in inhibition of DNA synthesis and cell death.","Treatment of cancer that utilizes antimetabolite substances to disrupt DNA, RNA, or protein synthesis.","An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.","An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.","A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.","An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.","A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.","A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.","An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.","A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxylesterase and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet.","A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite azacitidine, with potential antineoplastic activity. Upon oral administration of the cedazuridine/azacitidine combination agent ASTX030, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of azacitidine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of azacitidine. Azacitidine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase (DNMT), thereby blocking DNA methylation and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.","An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby 'rescuing' the patient while permitting the antitumor activity of 5-FU."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,false,true,false,false,true,true,false,false,true,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","TRUE","FALSE","TRUE","TRUE","TRUE","TRUE","FALSE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA"],["C164146","C981","C288","C26638","C1794","C66876","C807","C504","C408","C560","C876","C505","C642","C195","C513","C157079","C95209","C67088","C979","C2571","C1539","C153327","C868","C71537","C1057","C29341","C113444","C48813","C79803","C156680","C102856","C955","C1254","C1336","C1471","C1704","C73261","C2629","C1022","C994","C92589","C968","C1094","C1206","C877","C29794","C29019","C38719","C94728","C118288","C2353","C28793","C153133","C125690","C967","C62785","C113789","C64338","C15183","C115102","C116885","C111757","C11252","C105613","C125901","C128888","C102554","C150807","C99629","C67504","C171649","C125656","C120099"],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[null,"Nucleoside Metabolic Inhibitor [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Nucleoside Analog Antiviral [EPC]","Antimetabolite [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Antimetabolite [EPC]","Antimetabolite [EPC]","Nucleoside Metabolic Inhibitor [EPC]","Folate Analog Metabolic Inhibitor [EPC]","Nucleoside Metabolic Inhibitor [EPC]",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[2020,2006,2004,2004,1998,1996,1985,1970,1969,1967,1966,1962,1953,1953,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,3,3,2,2,2,2,2,2,1,1,1,1,1,1,1,1,0,0,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["acute myeloid leukemia, cancer","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adult lymphoma, blast phase chronic myelogenous leukemia, bcr-abl1 positive, breast cancer, breast neoplasm, burkitts lymphoma, cancer, central nervous system cancer, childhood acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, follicular thyroid carcinoma, head and neck malignant neoplasia, hodgkins lymphoma, leukemia, lymphoid neoplasm, lymphoma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, papillary thyroid carcinoma, pediatric lymphoma, peritoneum cancer, refractory anemia with excess blasts, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, angioimmunoblastic t-cell lymphoma, brain neoplasm, breast cancer, cancer, central nervous system cancer, childhood ependymoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, colorectal carcinoma, cutaneous melanoma, diffuse large b-cell lymphoma, ependymoma, esophageal cancer, follicular lymphoma, head and neck malignant neoplasia, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, leukemia, liposarcoma, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, mature t-cell and nk-cell non-hodgkin lymphoma, metastatic melanoma, multiple myeloma, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, refractory anemia with excess blasts, squamous cell carcinoma, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hodgkins lymphoma, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoma, multiple myeloma, neoplasm of mature b-cells, non-hodgkins lymphoma, t-cell non-hodgkin lymphoma","anus cancer, biliary tract cancer, biliary tract neoplasm, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, central nervous system cancer, cervical cancer, cholangiocarcinoma, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastric carcinoma, glioblastoma multiforme, glioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, liver cancer, lung cancer, male breast carcinoma, malignant colon neoplasm, malignant glioma, melanoma, mesothelioma, metastatic melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, peritoneum cancer, prostate cancer, rectal carcinoma, rectal neoplasm, rectum cancer, skin cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urothelial carcinoma","acute lymphoblastic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, cholangiocarcinoma, classic hodgkin lymphoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, endometrial cancer, endometrioid carcinoma, esophageal cancer, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gallbladder carcinoma, gallbladder neoplasm, gastric cancer, gastrointestinal stromal tumor, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hilar cholangiocarcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant epithelial tumor of ovary, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, mesothelioma, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, peritoneal neoplasm, peritoneum cancer, plasma cell leukemia, plasmacytoma, prostate cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, synovial sarcoma, t-cell non-hodgkin lymphoma, testicular carcinoma, thyroid cancer, triple-negative breast cancer, unspecified peripheral t-cell lymphoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm","acute myeloid leukemia, breast cancer","cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, esophageal cancer, fallopian tube cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver cancer, malignant colon neoplasm, ovarian cancer, peritoneum cancer, rectum cancer","acute basophilic leukemia, acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, brain neoplasm, breast cancer, burkitts lymphoma, childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, classic hodgkin lymphoma, diffuse large b-cell lymphoma, essential thrombocythemia, follicular lymphoma, glioblastoma multiforme, granulocytic sarcoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, juvenile myelomonocytic leukemia, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mantle cell lymphoma, medulloblastoma, melanoma, multiple myeloma, myeloid sarcoma, myeloproliferative disorder, neoplasm of mature b-cells, non-hodgkins lymphoma, ovarian cancer, plasma cell leukemia, polycythemia vera, prostate cancer, refractory anemia, refractory anemia with excess blasts, sarcoma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, desmoid-type fibromatosis, esophageal cancer, essential thrombocythemia, gastric cancer, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, laryngeal neoplasm, leukemia, lung cancer, lymphoma, melanoma, meningioma, myeloproliferative disorder, oral cavity cancer, paranasal sinus neoplasm, pharynx cancer, polycythemia vera, squamous cell carcinoma","acute basophilic leukemia, acute erythroleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, brain cancer, brain neoplasm, childhood acute lymphoblastic leukemia, chronic myelomonocytic leukemia, glioblastoma multiforme, hodgkins lymphoma, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, myeloproliferative disorder, non-hodgkins lymphoma, refractory anemia, refractory anemia with excess blasts, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","actinic keratosis, anal carcinoma, anal neoplasm, anus cancer, basal cell carcinoma, biliary tract cancer, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, central nervous system cancer, cervical cancer, cervical intraepithelial neoplasia, cholangiocarcinoma, chronic myeloproliferative disorder, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, ependymoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, laryngeal carcinoma, laryngeal neoplasm, liver cancer, lymphoma, malignant colon neoplasm, melanoma, metastatic melanoma, mucinous carcinoma, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, peritoneal neoplasm, peritoneum cancer, pharynx cancer, rectal carcinoma, rectum cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine neoplasm","acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast neoplasm, burkitts lymphoma, cancer, cervical cancer, childhood acute lymphoblastic leukemia, childhood ependymoma, choriocarcinoma, choroid plexus neoplasm, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, colorectal cancer, colorectal carcinoma, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, extranodal nasal nk/t cell lymphoma, follicular lymphoma, gestational trophoblastic neoplasm, hairy cell leukemia, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, hydatidiform mole, juvenile myelomonocytic leukemia, kidney cancer, langerhans cell histiocytosis, leukemia, lung cancer, lymphoblastic lymphoma, lymphoid leukemia, lymphoid neoplasm, lymphoma, malignant pleural mesothelioma, mantle cell lymphoma, medulloblastoma, mesothelioma, multiple myeloma, mycosis fungoides, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, neurofibromatosis type 1, non-hodgkins lymphoma, osteosarcoma, ovarian cancer, ovarian carcinoma, plasma cell leukemia, polycythemia vera, primitive neuroectodermal tumor, refractory anemia, refractory anemia with excess blasts, sarcoma, sezary's disease, squamous cell carcinoma, t-cell acute lymphoblastic leukemia, t-cell large granular lymphocyte leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, waldenstrom macroglobulinemia","acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, anaplastic astrocytoma, anaplastic oligodendroglioma, b-cell acute lymphoblastic leukemia, brain neoplasm, cancer, childhood acute lymphoblastic leukemia, glioblastoma multiforme, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mixed glioma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","biliary tract cancer, biliary tract neoplasm, breast cancer, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, nasopharyngeal neoplasm, neoplasm of esophagus, non-small cell lung carcinoma, oral squamous cell carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, rectal carcinoma, rectum cancer, small cell lung carcinoma, stomach neoplasm, urinary bladder cancer","colonic neoplasm, colorectal neoplasm, osteosarcoma, rectum cancer","acute myeloid leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, lung cancer, metastatic melanoma, myeloproliferative disorder, ovarian cancer, small cell lung carcinoma, urothelial carcinoma","colorectal carcinoma, pancreatic carcinoma","cancer, lung cancer","colorectal carcinoma, multiple myeloma","cancer, colorectal neoplasm, esophageal carcinoma, stomach neoplasm","acute lymphoblastic leukemia, acute myeloid leukemia","head and neck malignant neoplasia, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma","chronic lymphocytic leukemia","leukemia","cancer, leukemia, non-small cell lung carcinoma","pancreatic carcinoma, urinary bladder cancer","hematopoietic and lymphoid cell neoplasm, lymphoma, rectal carcinoma","cancer","cancer, colorectal adenocarcinoma","cancer","cancer","cancer","acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, cancer, chronic lymphocytic leukemia, chronic myeloproliferative disorder, hairy cell leukemia, histiocytosis, langerhans cell histiocytosis, leukemia, lymphoma, malt lymphoma, mantle cell lymphoma, multiple myeloma, myeloid leukemia, systemic mastocytosis, unspecified peripheral t-cell lymphoma","hepatocellular carcinoma, kaposi's sarcoma, lymphoma, non-hodgkins lymphoma, small cell lung carcinoma","acute lymphoblastic leukemia, cancer, chronic myeloproliferative disorder, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, multiple myeloma, mycosis fungoides, sezary's disease, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, al amyloidosis, anaplastic astrocytoma, anaplastic oligodendroglioma, angioimmunoblastic t-cell lymphoma, breast cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, gliosarcoma, hairy cell leukemia, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hodgkins lymphoma, leukemia, lung cancer, lymphoma, malt lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, multiple myeloma, neoplasm of mature b-cells, non-hodgkins lymphoma, ovarian cancer, plasma cell leukemia, unspecified peripheral t-cell lymphoma, waldenstrom macroglobulinemia","chronic lymphocytic leukemia, lymphoma, nasopharyngeal neoplasm","","","","","","","","","","","","","","","","","cancer","","","","","","","","","","","","","","","","","",""],["1|2","0|1|2|3|4","0|1|2|3|4","1|2|3|4","1|2|3|4","0|1|2|3|4","1|2","1|2|3|4","1|2|3|4","1|2|3|4","1|2|3","0|1|2|3|4","1|2|3|4","2|3|4","1|2|3|4","1|3","1|2|3","1|2","1|2","1|2","1|2","1|2","0|1|2","1","1","1","1","1","1","1","1","0","0","1|2|3|4","2|3","1|2|3|4","1|2|3|4","1|2","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>immune_checkpoint_inhibitor<\/th>\n      <th>topoisomerase_inhibitor<\/th>\n      <th>iap_inhibitor<\/th>\n      <th>tubulin_inhibitor<\/th>\n      <th>kinase_inhibitor<\/th>\n      <th>hdac_inhibitor<\/th>\n      <th>parp_inhibitor<\/th>\n      <th>bet_inhibitor<\/th>\n      <th>monoclonal_antibody<\/th>\n      <th>antimetabolite<\/th>\n      <th>angiogenesis_inhibitor<\/th>\n      <th>alkylating_agent<\/th>\n      <th>anthracycline<\/th>\n      <th>platinum_compound<\/th>\n      <th>proteasome_inhibitor<\/th>\n      <th>hormone_therapy<\/th>\n      <th>hedgehog_antagonist<\/th>\n      <th>fda_epc_category<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indicaton_max_phase<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,31,32]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
</div>
</div>
<div class="section level2">
<h2 id="session-info">Session Info<a class="anchor" aria-label="anchor" href="#session-info"></a>
</h2>
<div class="sourceCode" id="cb7"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="co"># set eval = FALSE if you don't want this info (useful for reproducibility) </span></span>
<span><span class="co"># to appear</span></span>
<span><span class="fu"><a href="https://rdrr.io/r/utils/sessionInfo.html" class="external-link">sessionInfo</a></span><span class="op">(</span><span class="op">)</span></span>
<span><span class="co">#&gt; R version 4.2.2 (2022-10-31)</span></span>
<span><span class="co">#&gt; Platform: x86_64-pc-linux-gnu (64-bit)</span></span>
<span><span class="co">#&gt; Running under: Ubuntu 22.04.1 LTS</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; Matrix products: default</span></span>
<span><span class="co">#&gt; BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3</span></span>
<span><span class="co">#&gt; LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; locale:</span></span>
<span><span class="co">#&gt;  [1] LC_CTYPE=C.UTF-8       LC_NUMERIC=C           LC_TIME=C.UTF-8       </span></span>
<span><span class="co">#&gt;  [4] LC_COLLATE=C.UTF-8     LC_MONETARY=C.UTF-8    LC_MESSAGES=C.UTF-8   </span></span>
<span><span class="co">#&gt;  [7] LC_PAPER=C.UTF-8       LC_NAME=C              LC_ADDRESS=C          </span></span>
<span><span class="co">#&gt; [10] LC_TELEPHONE=C         LC_MEASUREMENT=C.UTF-8 LC_IDENTIFICATION=C   </span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; attached base packages:</span></span>
<span><span class="co">#&gt; [1] stats     graphics  grDevices utils     datasets  methods   base     </span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; other attached packages:</span></span>
<span><span class="co">#&gt; [1] pharmOncoX_1.1.4</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; loaded via a namespace (and not attached):</span></span>
<span><span class="co">#&gt;  [1] bslib_0.4.2       compiler_4.2.2    pillar_1.8.1      jquerylib_0.1.4  </span></span>
<span><span class="co">#&gt;  [5] tools_4.2.2       digest_0.6.31     jsonlite_1.8.4    googledrive_2.0.0</span></span>
<span><span class="co">#&gt;  [9] evaluate_0.19     memoise_2.0.1     lifecycle_1.0.3   gargle_1.2.1     </span></span>
<span><span class="co">#&gt; [13] tibble_3.1.8      pkgconfig_2.0.3   rlang_1.0.6       cli_3.6.0        </span></span>
<span><span class="co">#&gt; [17] crosstalk_1.2.0   curl_4.3.3        yaml_2.3.6        pkgdown_2.0.7    </span></span>
<span><span class="co">#&gt; [21] xfun_0.36         fastmap_1.1.0     httr_1.4.4        withr_2.5.0      </span></span>
<span><span class="co">#&gt; [25] dplyr_1.0.10      stringr_1.5.0     knitr_1.41        htmlwidgets_1.6.1</span></span>
<span><span class="co">#&gt; [29] generics_0.1.3    desc_1.4.2        fs_1.5.2          vctrs_0.5.1      </span></span>
<span><span class="co">#&gt; [33] sass_0.4.4        systemfonts_1.0.4 DT_0.26           tidyselect_1.2.0 </span></span>
<span><span class="co">#&gt; [37] rprojroot_2.0.3   glue_1.6.2        R6_2.5.1          textshaping_0.3.6</span></span>
<span><span class="co">#&gt; [41] fansi_1.0.3       rmarkdown_2.19    purrr_1.0.1       lgr_0.4.4        </span></span>
<span><span class="co">#&gt; [45] magrittr_2.0.3    ellipsis_0.3.2    htmltools_0.5.4   assertthat_0.2.1 </span></span>
<span><span class="co">#&gt; [49] ragg_1.2.4        utf8_1.2.2        stringi_1.7.8     cachem_1.0.6     </span></span>
<span><span class="co">#&gt; [53] crayon_1.5.2</span></span></code></pre></div>
<p><br><br></p>
</div>
<div class="section level2">
<h2 class="unnumbered" id="references">References<a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-Freshour2021-bh" class="csl-entry">
Freshour, Sharon L, Susanna Kiwala, Kelsy C Cotto, Adam C Coffman,
Joshua F McMichael, Jonathan J Song, Malachi Griffith, Obi L Griffith,
and Alex H Wagner. 2021. <span>â€œIntegration of the
<span>Drug-Gene</span> Interaction Database (<span>DGIdb</span> 4.0)
with Open Crowdsource Efforts.â€</span> <em>Nucleic Acids Res.</em> 49
(D1): D1144â€“51. <a href="http://dx.doi.org/10.1093/nar/gkaa1084" class="external-link">http://dx.doi.org/10.1093/nar/gkaa1084</a>.
</div>
<div id="ref-Kim2021-ye" class="csl-entry">
Kim, Sunghwan, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian
He, Qingliang Li, et al. 2021. <span>â€œ<span>PubChem</span> in 2021: New
Data Content and Improved Web Interfaces.â€</span> <em>Nucleic Acids
Res.</em> 49 (D1): D1388â€“95. <a href="http://dx.doi.org/10.1093/nar/gkaa971" class="external-link">http://dx.doi.org/10.1093/nar/gkaa971</a>.
</div>
<div id="ref-Nakken2022-ab" class="csl-entry">
Nakken, Sigve. 2022. <em>phenOncoX: A Phenotype Ontology Map for
Cancer</em>. <a href="https://github.com/sigven/phenOncoX" class="external-link">https://github.com/sigven/phenOncoX</a>.
</div>
<div id="ref-Ochoa2021-jc" class="csl-entry">
Ochoa, David, Andrew Hercules, Miguel Carmona, Daniel Suveges, Asier
Gonzalez-Uriarte, Cinzia Malangone, Alfredo Miranda, et al. 2021.
<span>â€œOpen Targets Platform: Supporting Systematic Drug-Target
Identification and Prioritisation.â€</span> <em>Nucleic Acids Res.</em>
49 (D1): D1302â€“10. <a href="http://dx.doi.org/10.1093/nar/gkaa1027" class="external-link">http://dx.doi.org/10.1093/nar/gkaa1027</a>.
</div>
<div id="ref-Sioutos2007-nl" class="csl-entry">
Sioutos, Nicholas, Sherri de Coronado, Margaret W Haber, Frank W Hartel,
Wen-Ling Shaiu, and Lawrence W Wright. 2007. <span>â€œ<span>NCI</span>
Thesaurus: A Semantic Model Integrating Cancer-Related Clinical and
Molecular Information.â€</span> <em>J. Biomed. Inform.</em> 40 (1):
30â€“43. <a href="http://dx.doi.org/10.1016/j.jbi.2006.02.013" class="external-link">http://dx.doi.org/10.1016/j.jbi.2006.02.013</a>.
</div>
</div>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by <a href="https://github.com/sigven" class="external-link">Sigve Nakken</a>.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
